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ABSTRACT 
Background & Objectives: 
 A prospective study was carried out to find the 
variations in lipid profile in smokers when compared to 
non-smokers. To study the alterations in lipid profile in 
terms of severity of smoking.  
Materials and Methods: 
 This study was carried out among 200 patients who 
attended Government Rajaji Hospital, Madurai., for various 
ailments. The population was divided into 100 non-smokers 
and 100 smokers. The smokers were further divided into 
three groups depending on the intensity of smoking. Serum 
lipid profile was analyzed in all subjects.  
 
 
 
Results: 
Lipid Profile Non-Smokers (Mean ± Std) 
Smokers 
(Mean ± Std) P-Value 
TC 161.18±26.77 191.96±31.37 < 0.001 
TG 103.58±26.26 164.29±28.95 < 0.001 
HDL 49.58±8.57 44.72±9.96 = 0.002 
LDL 82.34±16.57 103.08±18.66 < 0.001 
VLDL 21.69±6.42 29.02±8.98 < 0.001 
  
Dyslipidemia was directly proportional to intensity of 
smoking. 
 
Interpretation and Conclusion: 
Increase in total Cholesterol, Triglycerides, LDL & VLDL 
were found in smokers of all age groups. Where as HDL 
values showed inverse relationship. These changes were 
directly proportional to the severity of smoking. So, 
Tobacco smoking is associated with dyslipidemia which is 
atherogenic in nature.  
 
Keyword: 
Cigarette Smoking, Total Cholesterol, Triglycerides, Low 
density lipoprotein, High density Lipoprotein, Very low 
density Lipoprotein. 	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1. INTRODUCTION 
Tobacco is one of the most potent and prevalent addictive, influencing 
behavior of human beings for over 4 centuries. Smoking is now rapidly 
increasing through the developing world and is one of the biggest threats to 
current and future health. Cigarette smoking is the most common type of 
tobacco use. Tobacco continues to be the second major cause of death in the 
world. Smoking is an important risk factor for atherosclerosis, peripheral 
vascular disease and stroke and cancers. It also has a strong relationship with 
gastric ulcer, periodontal disease and metabolic syndrome. 
Cigarette smoking leads to the uptake of many hazardous compounds 
and their metabolites extracted from burning tobacco. The substances may 
be electrophilic and react with biological molecules giving rise to oxidative 
stress through the formation of reactive species or the initiation of lipid 
peroxidation chains in the membranes. Cigarette smoking has been found to 
alter the lipoprotein levels.  
A one to three fold increase in risk of myocardial infarction has 
generally been noted among smokers. Plasma lipoprotein abnormalities are 
said to be the major underlying risk factor for the common occurrence of 
atherosclerotic vascular disease. Most of the studies indicate definite 
correlation between smoking and lipid profile alteration in which there is 
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definite dose response relationship between the number of cigarette smoking 
as well as the duration of smoking and changes in the lipid profile noted.  
However, in spite of all these information there is still much controversy 
about which part or parts in the lipid profile are mainly altered in response to 
cigarette smoking.  
 In the present study, an attempt has been made to find out the effect of 
smoking on the lipid in the health smokers are compared with that of same 
age group healthy non-smokers.  
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2. AIMS AND OBJECTIVES 
 
• Comparative study of lipid profile among smokers and non-
smokers. 
• To study variable patterns of lipid profile in terms of intensity of 
smoking. 
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3. REVIEW OF LITERATURE 
HISTORICAL ASPECTS 
 Tobacco has been used for centuries and possibly for millennia. At 
first it was smoked only by the native population of America and it was 
introduced to Columbus; but subsequently after tobacco was brought to 
Europe in the middle century, smoking became widespread throughout the 
world. 
It was introduced to European society by Columbus after his 
maiden trip to the America in 1642. In Cuba he met a party of Tairo 
Indians with firebrand in their hands and herbs to inhale the smoke 
through the nostrils. This spread the use of tobacco from the American 
to Spain and European nation and ultimately all over the world. 
When tobacco was first introduced into Europe, smoking was 
recommended for medicinal purposes; but its value soon became 
controversial. It was praised as prophylactic against many ills and 
condemned as a noxious vice, one of its notable opponents being James 
I, king of United Kingdom, who wrote vehemently against it and 
published in 1604 a treaty, a counterblast to tobacco, that smoking was 
harmful to brain, lungs, eyes and nose, however it was good for tax 
rolls. 
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Jeam Nicot extolled the medicinal values of tobacco which was 
supposed to cure various diseases including gout!. Thus tobacco 
became Nicotiana in honor of Nicot. 
The association between atherosclerosis and tobacco smoking 
was noted by Buerger during earlier years of 20th  century. He observed 
ischemia of limbs (distally) among young smokers. 
The risk of CAD decreases on cessation of smoking. This 
reduction in risk is significantly greater in a year of stopping smoking 
and there after gradually decreases until, after 10-20 years it is same as 
that of non-smokers. According to combined study of Alban and 
Framingham the smokers are at a 3 fold increased risk of acute 
coronary syndromes when compared with non-smokers of similar age 
groups. 
In the past two decades, the rate of tobacco use was reduced in 
well-developed countries. So now the tobacco industries are targeting 
the nations, which are developing, and they are expanding their markets 
in those nations. About a third of the smoking population resides in 
china. This population is more than the smoking population in Europe 
and U.S. combined. According to WHO, by 2020, about three fourth of 
tobacco associated deaths will be occurring in the developing and under 
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developed nations. The death due to tobacco related illness crosses one 
million per year in china. This rate is 2.5 times more than that observed 
in U.S.  
The effect on mortality is proportionally greater in male smokers 
than female smokers. But mortality in females is also increased when 
compared with non smoking females. 
EPIDEMIOLOGY OF SMOKING 
 WHO has published a global fact-sheet regarding tobacco usage 
in countries as well as the effect of tobacco on mortality and morbidity. 
According to them  
• Globally around one third of the adult males practice tobacco 
smoking. 
• Smoking will be the cause of death in 1 among 6 persons by 2030 
if the present trend persists. Globally 1 among 10 adults will be 
dying of smoking associated illness or it will be responsible for 
more than 4 millon deaths annually. 
• One death occurs in each 8 seconds because of smoking tobacco. 
• The habit of tobacco smoking is increasing greatly in developing 
countries. It tends to decline in well-developed nations. It was 
noted that there was a 50% reduction in the rate of smoking 
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tobacco among American population in the past few decades. The 
use of tobacco is rising by 3.5% every year in the developing 
countries. 
• More than 9.8 million cigarettes are being sold each minute and 
more than 14.5 billion cigarettes are being sold every day. 
• The tobacco related deaths in Britain citizens is 12 times more 
compared to the deaths from Second World War. 
• 1 among 5 in American population die of tobacco associated 
illness. 
• In WHO regions, maximum smoking rates were observed in west 
pacific areas. In these areas about 2/3 of adult males smoke. 
• In the west pacific areas 1 among every 3 cigarettes are used. 
• The tobacco trade is influenced mainly by the following 
corporations- japan, Britain and America. 
YOUTH: 
• Globally 1 adolescent in every 5 smoke. 
• Everyday around 90,000 children begin smoking, globally. More 
than 50% of them are in Asian continent. 
• It was observed that about half of those who begin smoking in 
teen age continue smoking for more than 20 years.  
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• Studies show that adolescents are much influenced by the 
advertisements for cigarettes. 
• One fourth of the teenagers of west pacific areas will face death 
because of tobacco associated illness. 
HEALTH 
• Smoking 1 cigarette reduces five minutes in life span. About 50% 
of chronic smokers will be dying due to smoking associated 
illness. 
•  The single most preventable cause of premature death and illness 
is tobacco smoking. It happens to be the important factor in 
stroke, coronary artery disease and chronic obstructive 
pulmonary disease. It can cause cancers of the pharynx, larynx, 
oral cavity and lungs. It is also related to cancers of esophagus, 
stomach and urinary bladder. It is also related to cancers of 
pancreas, liver, ureters and kidney. 
• Several harmful chemicals are found in the smoke from tobacco. 
A survey in Britain showed that more than 90% of females are 
unaware of the association of cancer of cervix with tobacco 
smoking. 
• A survey was conducted in china, which showed that more than 
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sixty percent of adults in china were not aware of the association 
between cancer of lung and tobacco. About ninety five percent 
were not aware that smoking could cause coronary artery disease. 
• About 1/4th of deaths due to CAD and 3/4th of deaths due to 
COPD are associated with smoking tobacco. 
• More than one fifty million dollars are spent in U.S. for tobacco-
associated diseases.  
ADVERTISING 
• US-based multinational Philip Morris-the world’s biggest 
cigarette company-was the world’s ninth largest advertiser in 
1996, spending more than $3 billion. 
• A survey a few years ago found that nearly 80% of American 
advertising executives from top agencies believed cigarette 
advertising does makes smoking more socially acceptable to 
children. 
• Through advertising, tobacco firms try to link smoking with 
athletic prowess, sexual attractiveness, success, adult 
sophistication, adventure and self-fulfillment.  
• A survey in the UK found half of smokers think that smoking 
“can’t really be all that dangerous, or the Government wouldn’t 
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have let cigarettes be advertised”. 
• A 1998 survey found that tobacco companies were among the top 
10 advertisers in 18 out of 66 countries surveyed. 
• In Asia, tobacco companies are among the top 10 advertisers 
Cambodia, Indonesia, Malaysia, Myanmar, and the Philippines. 
• In Russia, according to press reports, foreign tobacco companies 
are the largest advertisers, accounting for as much as 40% of all 
TV and radio advertising. 
• In 1997, the tobacco industry’s spending on advertising in the 
United States was about $15 million a day ($5.7 billion for the 
year). 
• The tobacco industry has changed the way it advertises in the last 
30 years. Now only 10% of advertising expenditure goes to print, 
and outdoor advertisement, while more than half goes to 
promotional allowances and items, such as t-shirts for young 
people or lighters and key rings. 
PGIMER Chandigarh recently carried out an analysis on the 
prevalence cigarette smoking in India. The study was carried out in 4 
centers in India. The study group included people more than fifteen 
years of age. A detailed list of questions was prepared for the survey. 
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There were 11496(15.6%) ever smokers in the study sample of 73605 
subjects. Among 37,682 males, 10,756(28.5%) were ever smokers and 
among 35,923 females, 740(2.1%) were ever smokers. Bidis were the 
most common form of smoking particularly in rural areas. The mean 
number of cigarette/bidis smoked per day was 14(±11.5) and the mean 
age of starting smoking 20.5(±20.0) years. The important agents associated 
with tobacco smoking were poverty and advancing age. The tobacco control 
programmes took strict measures against tobacco, which resulted in a 
cessation rate of around 11%. Around 15% of chronic smokers had 
respiratory problems. They concluded that a significant population in India 
has smoking habit (present or past) with the prevalence more in males 
compared to females. In spite of various anti tobacco measures the cessation 
rates were found to be very low. It was found that there was a significant 
smoking associated respiratory morbidity.  
TYPES OF SMOKING 
The practice of tobacco smoking is carried in a number of different 
ways to achieve one single goal: to obtain the nicotine kick, which is derived 
from the habit. Some of the different ways of smoking include: 
• Cigarette 
o A paper wrapped cylinder, containing tobacco (which is 
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cured and finely cut) along with reconstituted tobacco and 
additives. 
o May have filters at one end. 
 
Fig.1. Cigarettes 
• Bidis 
 
Fig.2. Bidis 
o These are thin, hand rolled cigarettes. 
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o Primarily produced in India and some Southeast Asian 
countries and imported to United States. 
o Tendu or temburni leaf is used for wrapping the tobacco. 
o A string is used for securing the ends. 
o May be flavored or non flavored. 
o Found to be more addictive when compared to normal 
cigarettes. 
o More concentration of tar, carbon monoxide and  nicotine 
are present. 
• Cigars, cigarillos and little cigars: 
 
Fig.3. Cigars 
o Produced from air cured or dried tobacco. 
o The tobacco leaves for cigar are initially aged for 1 year. 
o Then in a multistep process, they are fermented. 
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o This process again can take upto 5 months. 
o Bacterial and chemical reactions due to the process of 
fermentation produce alterations in the tobacco. 
o This gives a distinct smell and taste to cigars. 
o Compared to cigarettes regular cigars are larger. They wont 
be having filters. 
o Little cigars or cigarillos will be similar to cigarettes. They 
will have filters and are filled with pipe tobacco. 
Sometimes they will be flavored. 
o Compared to cigarettes, cigars have larger amounts of 
nicotine. 
• Kreteks: 
 
Fig.4. Kreteks 
o These are often called clove cigarettes. 
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o Combination of cloves, tobacco, and other additives. 
o Imported from Indonesia. 
o The smoke contains large amounts of tar, carbon monoxide, 
and nicotine when compared to routine cigarettes. 
o Users are found to have higher risk of acute lung injury. 
• Pipes  
 
Fig.5. Pipe 
o Have a chamber, stem and mouth piece. 
o Inside the bowl tobacco will be placed and lit. 
• Hookah: 
o A type of pipe used for smoking shisha. 
o Tobacco along with vegetables or fruits is heated. 
o The smoke produced is filtrated through water. 
o The pipe has a head, body, water bowl and a hose. 
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o Charcoal is used for heating in the hookah. 
 
Fig.6. Hookah 
Electronic or E-cigarette: 
 
Fig.7. E-Cigarette 
• These are devices having a cadridge that is filled with nicotine, 
flavor and chemicals. 
• The device is battery powered. 
• This is a nicotine delivering system. 
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• This is not a tobacco product. 
• The ingredients of e-cigarettes will be turned into vapour, which 
will be inhaled by the user. 
• Here no tobacco burning is involved. 
• No smoke will be produced. 
• Only a fine heated mist is produced. 
• Often resembles a real cigarette. 
• Some other types look like a ballpoint pen. 
• These are reusable. 
• Replaceable and refillable cadridges are available. 
• Available in different flavors and with different levels of 
nicotine. 
• Marketed as an alternative and an aid in quitting tobacco. 
• But no evidences are there to confirm the safety of e-cigarettes. 
 
CONTENTS OF THE CIGARETTE SMOKE 
1. Gaseous substance 
a. Hydrogen cyanide 
b. Carbon monoxide 
c. Nitrogen oxides 
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2. Volatile chemicals 
a. Benzene 
b. Acrolein 
c. Formaldehyde 
d. N-nitrosoamines 
3. Sub-micron sized particle suspended in the smoke like 
a. Phenol 
b. Poly aromatic hydro carbons 
c. Nicotine 
d. Tobacco specific nitrosoamines 
 
Fig.8. Contents of Cigarette Smoke 
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TABLE: 1. List of Contents in Cigarette Smoke 
CHEMICAL AMOUNT(PER CIGARETEE) 
Acetaldehyde 980 micrograms to 1.37 milligrams 
Acrylonitrile Formally 1to 2 milligrams. This 
product was used as a fumigant in 
tobacco. Its use has since been 
discontinued 
4-Aminobiphenyl 0.2 to 23 Nano grams per cigarette 
O-Anisidine-
Hydrocholoride 
Unknown 
Arsenic Unkown 
Benzene 5.9 to 75 micrograms 
Beryllium 0.5 Nano grams  
1,3-Butadiene 152 to 400 micrograms 
Cadmium 1.7 micrograms 
1,1-Dimethylhydrazine Unknown 
Ethylene oxide Unknown 
Formaldehyde Unknown 
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Furan Unknown 
Heterocyclic amines Unknown 
Hydrazine 32 micrograms 
Isoprene 3.1 milligrams 
Lead Unknown 
2-Nahthylamine 1.5 to 35 Nano grams 
Nitromethane Unknown 
N-Nitrosodi-n-Butylamine 3 Nano grams 
N-Nitrosodiethanolamine 24 to 36 Nanograms 
N-Nitrosodiethylamine Up to 8.3 Nanograms 
N-Nitrosodimethylamine 5.7 to 43 nanograms 
N-Nitrosodi-n-
Propylamine 
1 Nanogram 
4-(N-Nitrosom-
ethylamine)-1-(3-Pyridyl)-
10Butanone 
Upto 4.2 micrograms 
N-Nitrosonomicotine 14 microgram 
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N-Nitrosopiperidine Unknown  
N-Nitrosopyrrolidine 113 Nanograms 
N-Nitrososarcosine 22 to 460 nanograms 
Polonium-210  Variable, depending on soil and 
fertilizer used to grow tobacco 
Polycyclic hydrocarbon 28 to 100 milligrams 
O-Toluidine 32 Nanograms 
Vinyl chloride 5.6 to 27 Nanograms 
 
CHARACTERISTICS OF SMOKERS 
Many features distinguish smokers from non-smokers 
• They tend to have increased amount of tea, coffee 
• They consume more alcohol 
• They have reduced exercise performance 
• They have weaker immune mechanisms 
• They have a small increase in the total white blood cell count, 
hematocrit, serum IgE levels, and platelets count. 
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• They have reduced levels of leucocyte ascorbic acid. 
• Their serum levels of albumin are less compared to non smokers. 
• Their serum uric acid levels are less 
• They have reduced HDL to LDL ratio 
• Their leucocyte counts show a strong inverse relationship with HDL 
cholesterol, a positive association with triglycerides and LDL 
cholesterol in smokers. 
• There is reduced synthesis of PGI2, a potent vasodilator, a 
cyclooxygenase product of vascular endothelium and an inhibitor of 
platelet aggregation. 
• They have increased number of pulmonary macrophages which show 
altered metabolism 
• They are found to have abnormal results in lung function tests. 
• Tobacco smoking is found to stimulate hepatic microsomal enzyme 
systems and interact with a lot of drugs like  
o Propranolol-augmented first pass clearance 
o Propoxyphene-reduced analgesic effect 
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o Benzodiazepines-reduced sedative effect 
o Beta blockers-heart rate and blood pressure lowering effect are 
reduced 
o Chlorpromazine-reduced serum levels 
o Oral oestrogens-increased clearance by liver 
o Haloperidol-reduced serum concentrations 
o Heparin-faster clearance 
o Insulin- reduced absorption due to cutaneous vasoconstriction. 
SMOKING AND LIPID PROFILE 
The various mechanisms postulated in the alteration of lipid profile 
among smokers are 
• Stimulation of sympatho adrenal system by nicotine leading to 
lipolysis and increased serum free fatty acid(FFA) levels which leads 
to increased synthesis of VLDL from the liver , hence increased 
triglycerides(increased consumption  of  FFA by heart that leads to 
increased myocardial oxygen demand). 
• HDL concentration varies inversely with VLDL concentration in 
serum. 
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• Repressive action of smoking on oestrogen level in turn leads to 
decreased HDL cholesterol  
• Smokers are thought to consume diet rich in fat and cholesterol and 
poorer in fibres and serials. 
• Difference in oral fat handling between smokers and non smokers. 
Smoking of tobacco by people, started centuries ago but the health 
and environmental hazards posed by it was recognized only in the 20th 
century. Atherogenesis leading to coronary artery disease and 
cerebrovascular accidents is thought to be accelerated by smoking. The exact 
atherogenic mechanism of smoking is still unclear. It has been observed by 
workers that smoking leads to dyslipidemia which is a major factor for 
atherosclerosis. 
Gofman JW et al were the early pioneers of this study and had found 
that cigarette smoking and serum lipoproteins had a strong association 
between themselves as well as coronary artery disease. The initial 
examination revealed that 82 subjects had clinically evident CAD. They 
were excluded from the sample leaving a total of 5127. 4469 (69%) of the 
6567 in the initial sample actually underwent the first examination. After the 
first examination, the study population was examined at intervals of two 
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years. Information was obtained with regard to serum cholesterol, blood 
pressure, weight and cigarette smoking. Although biennial examination was 
the main source of follow up information, other means were also adopted to 
detect CHD (example: death certificate records). 
Among other things, the study showed that increasing serum 
cholesterol values are associated with increased CHD risk. The study also 
showed that the association between smoking and CHD varied with 
manifestations of the disease. Thus smoking was most strongly associated 
with sudden death from CAD than with less fatal forms of the disease. Risk 
factors have been found include male sex, advancing age, high serum lipid 
concentration, high blood pressure, cigarette smoking, diabetes mellitus, 
obesity, low vital capacity and certain ECG abnormalities. The predictive 
value of serum lipids, blood pressure and cigarette smoking were repeatedly 
demonstrated. The Framingham heart study became a prototype of similar 
studies in US and other countries. 
FELIC study showed that development of coronary artery disease 
(atherosclerosis) begins in childhood itself. It is therefore important to 
identify potential risk factors early when prophylactic care can be cost 
effective (example; cigarette smoking).  
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Wendy H Graingetal demonstrated significantly higher serum levels 
of triglycerides(+11.8%), VLDL(+12.4%) and LDL(+4.1%) and lower level 
of HDL(-8.5%) and TC(-3-7%). This study was in the age group of 8-19 
years old. These changes were comparable with the changes seen in adult 
smokers except for total cholesterol, which is usually high in adult smokers. 
Misawa K and his colleagues ascertained the relationship among HDL, 
cholesterol and other serum lipids with active and passive smoking, obesity, 
alcohol drinking and working status in healthy adults and in school children 
sampled at random who were medically healthy. They found that 
triglycerides were high and had a direct relation to smoking while high-
density lipoprotein were low and had an inverse relationship to the number 
of cigarettes.  
Freedman DS et al from Bogalusa Heart study reported that in 
smokers following a fat rich meal, concentration of triglycerides increases to 
a greater degree and remains elevated for longer duration. Smoking 
promotes atherosclerosis by several mechanisms. Richmond W et al from 
st.mary’s hospital, London proposed that HDL changes and reduced removal 
of TGL rich lipoproteins, expose the endothelium of blood vessels to the 
atherogenic lipoproteins and there is increased predisposition to develop 
CHD.  
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Jensen J and Christiansen C in their study on serum lipoproteins 
during hormone replacement therapy and effects of smoking, found that total 
serum cholesterol was significantly reduced in smokers and non smokers but 
the response in smokers was only half of that observed in non smokers. 
Difference was also noticed in subjects with different modes of hormone 
administration. Response was better in those using the percutaneous route 
than the oral route.  
Largue G etal reported one experimental study with the use of 
nicotine gum on variation in total cholesterol and LDL cholesterol. They 
studied lipid modification in 14 voluntary students, heavy smokers (more 
than 20 cigarette per day) and nicotine dependents (Fager storm test scores > 
7). They received in double blind study, either 2mg nicotine gums or 
placebo gums (8-12 gums a day for one month). Total cholesterol, HDL 
cholesterol, LDL cholesterol and triglycerides were measured at day 0 and 
day 60. They found that at day 60 HDL and LDL cholesterol were 
significantly improved in those who gave up smoking. It was noted that 
there was also improvement in nicotine dependent smokers who were on 
nicotine gums.  
Gerogesteiner and his associates, who studied the pathophysiology 
and natural history of atherosclerosis of coronary artery and its association 
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with elevated level of intermediate density lipoproteins, found that 
triglycerides were high among the groups with increased rate of cigarette 
smoking. 
Moffatt RJ from the department of nutrition, food and movement 
science, Florida reported on increase of HDL cholesterol levels after 
cessation of smoking. Tilwani RK and his associates who studied total 
cholesterol, triglycerides, LDL, VLDL, and HDL found that TGL, LDL, 
VLDL and cholesterol values were elevated among smokers than non 
smokers. 
Rastogi R and his associates studied lipid profile in 51 healthy male 
non-smokers and 152 healthy male smokers. In this study they included both 
beedi and cigarette smokers. Mean value of total cholesterol LDL, VLDL, 
triglycerides were high in all groups of smokers but the rise was more in 
heavy smokers and in persons who smoked for more than 20 years. When 
compared with non-smokers the mean value of serum HDL and cholesterol 
was lower in all groups of smokers. The difference was maximum in heavy 
smokers. 
Tiwari AK and his associates studied changes in body lipids in 
healthy people and CHD patients. 51 normal volunteers and 34 clinically 
established coronary heart disease patients were studied. 21 out of the 51 
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normal and 16 out of the 34 coronary heart disease patients were cigarette 
smokers. The cases were divided into two groups, Subjects aged 20-40yrs, 
the younger age group and 41-61 yrs., the older age group. TC and HDL 
cholesterol of all cases were determined .the ratio of total cholesterol to 
HDL cholesterol was significantly higher in all the normal and coronary 
heart disease smokers. Hence the higher level of ratio of total cholesterol to 
HDL an important parameter helps to ascertain the development of coronary 
heart disease in cigarette smokers. 
A study by Khurana M and associates on lipid profiles in cigarette 
smokers and tobacco chewers showed HDL cholesterol to be lower in these 
people when compared to controls. It was also found that both tobacco 
chewers and cigarette smokers have an equal dyslipidemia and there is a 
raised risk for coronary artery disease. 
PLASMA LIPIDS AND LIPOPROTEINS 
Chemistry of lipids: 
The lipids constitute a wide range of substances of biological origin. 
These are soluble in organic solvents and are poorly soluble in water. 
Metabolically lipids are more closely interrelated, being transported together 
in the plasma lipoproteins and sharing certain mechanisms 
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Lipids can be classified as follows: 
 
(a) 
 
(b) 
Fig. 9. (a) & (b) Classification of Lipids 
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Fatty Acids 
 They are present as such in minute concentration in plasma and cells. 
They are constituents of most lipid classes. They comprise a carboxylic acid 
group and a chain of hydrocarbon and are thus aliphatic monocarboxylic 
acids. The fatty acids are arbitrarily divided into those with long chain, 
medium and short chains. They are also grouped into saturated and 
unsaturated fatty acids depending on the absence or presence of a double 
bond respectively. The main saturated fatty acids are palmitic and stearic 
acids. Most of the fatty acids are carried mainly by albumin. Essential fatty 
acids are those, which cannot be synthesized in the body. Free fatty acids are 
immediately available energy sources and provide much of the energy 
requirements of the body. (Normal values range from 250-400 mg/dI) 
CHOLESTROL: 
 Cholesterol is a word from Greek. Chole=bile, sterols=solid, 
ol=alcohol. It is synthesized in all nucleated cells. 120 gram of cholesterol is 
available in a 60 kilogram man 
• Nervous system contains 30 gm 
• Muscles contain 30 gm 
• Adipose tissue has 30 gm 
• Skin contains 30 gm 
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• Blood has 10 gm 
• Spleen and liver contain 10 gm 
• Bone morrow has 5 gm 
• Alimentary tract has 3 gm 
• Adrenal gland has 2 gm 
It is a crystalline solid with yellow color. They have notched 
appearance when examined under microscope. It is soluble in chloroform 
and other fat solvents. It is absent in plants and prokaryotes, present in all 
animal tissues. It was associated from bile stones by Poulletier de la sale in 
1758. Chevreul ME characterized it in 1818. Heinrich Wiela got Nobel price 
in 1927 for enunciating the complete structure of cholesterol in 1918. 
FUNCTIONS: 
• Important component of cell membrane 
• Important in nerve conduction by its insulating effect on nerve fibres. 
• Important precursor for bile acids and salts. 
• Androgens, estrogens and glucocorticoids are derived from it. 
• 7-Dehydrocholesterol is the precursor for the synthesis of vitamin D3. 
• Cholesterol esters are formed when OH group of cholesterol is 
esterified to fatty acids. This occurs in the body by transfer of PUFA 
moiety by lecithin acyl transferase.  
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Fig. 10.  Structure of Cholesterol 
BIOSYNTHESIS OF CHOLESTEROL  
 All the carbon atoms for cholesterol synthesis are acquired from 
acetyl COA. The pathway for synthesis was described by sir John Comfort 
and Vladimir Prelog. In 1975 they got Nobel price for this. It is synthesized 
in many parts of the body like liver, adrenal cortex, ovaries, testes, and 
intestine. Nucleated cells including walls of arteries can synthesize 
cholesterol. The various enzymes required for the synthesis of cholesterol 
are available partly in cytoplasm and partly in endoplasmic reticulum.  
EXCRETION OF CHOLESTEROL  
 300 mg of cholesterol is present in an average diet. 700 mg of 
cholesterol is synthesized in the body in one day. 500 mg of cholesterol in 
excreted in bile and part of this is reabsorbed in intestines. Intestinal bacteria 
act upon the un absorbed cholesterol to form cholesterol and 
coprostanol(fecal sterols). The remaining 500 mg is used in forming bile 
acids. 
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Fig. 11. Biosynthesis of Cholesterol 
CHOLESTEROL AND LIVER: 
 Liver can synthesize cholesterol. It removes cholesterol from 
lipoprotein remnants. It forms bile acids from cholesterol. It excretes 
cholesterol through bile.  
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TRIGLYCERIDES 
 These are compounds of one molecule of glycerol united by ester 
bonds to fatty acids (3 molecules). If any 1 or 2 among those 3 hydroxyl 
groups of glycerol is esterified then they are called mono or triglycerides 
respectively. Triglycerides are an important energy store. Plasma 
triglycerides are derived from two sources. Exogenous, or dietary 
triglycerides are derived from food and circulate in the plasma in the form of 
chylomicrons. These are large, low-density particles, which are formed in 
intestinal epithelial cells and appear in the plasma soon after a meal. 
Chylomicrons deliver dietary triglycerides to the adipose and other tissues. 
In normal individuals, they are entirely cleared from plasma within 12 hours 
of fasting. 
 Endogenous triglycerides are derived primarily from hepatic 
conversation of carbohydrate and amino acids. Eighty percent of it circulates 
in plasma in the form of very low-density lipoproteins (VLDL), which 
transport triglycerides to adipose and other tissues. As triglycerides are 
removed, intermediate density lipoprotein is formed, some of which 
undergoes catabolism in the liver to low-density lipoprotein (LDL) particles. 
A small proportion (approximately 15 percent) of plasma triglycerides are 
carried in LDL and a tint fraction is contained in the high-density lipoprotein 
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(HDL) moieties. 1984 consensus panel divided plasma triglycerides levels 
into three categories: “normal” was defined as a TG level less than 250 
mg/dl and HTG was dichotomized into “borderline hypertriglyceridemia” 
(250 to 500 mg/dl) and “true hypertriglyceridemia” (>500mg/dl). Levels of 
TG greater than 100 mg/dl are usually due to chylomicronemia and are 
believed to be able to cause recurrent abdominal pain and pancreatitis. 
 
Fig.12. Lipid Metabolism 
Elevated triglycerides are clinically important owing to their direct 
relationship to pancreatitis, and their association with glucose intolerance 
and renal and hepatic disease. Triglycerides measurements, as part of lipid 
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evaluation for atherosclerotic risk, are important as they provide the only 
convenient and cost-effective method for routinely estimating LDL 
cholesterol. Their inverse relationship to HDL makes triglyceride 
measurements a cost effective screening procedure. Unlike cholesterol 
measurement, triglycerides should always be assessed in the fasting state. 
PHOSPHLIPIDS 
 They are complex lipids resembling triglycerides, but in addition to 
glycerol and fatty acids, they contain one or more phosphoric acid groups 
and a nitrogenous base. The major phospholipids in plasma are lecithin and 
sphingomyelin. The phosphate and nitrogenous base are water soluble, a fact 
that is important in lipid transport.  (Normal values range between 150-275 
mg%). 
LIPOPROTEINS OF PLASMA 
Lipids are insoluble in water. When lipids combine with water-soluble 
complex proteins, they become soluble and constitute lipoproteins. The role 
of protein-lipid complexes in maintaining the lipids in solution in plasma 
was suspected by Schulz(1897) and Nerking (1901) at the turn of 20
th 
century. Application of new physical methods for protein separation, 
including electrophoresis and ultracentrifugation expedited the progress in 
lipoprotein chemistry. Tiselius et al in 1941 reported the existence of two 
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lipoprotein classes, separable by moving boundary electrophoresis. These 
were alpha and beta lipoproteins. It was another decade before a further 
component; Pre-B lipoprotein was identified by zonal electrophoresis 
(DangerfieldWO,1955). 
CLASSIFICATION: 
• Chylomicrons contain apolipoprotein B-48. 
• Very low density lipoproteins or pre beta lipoproteins. B-100 is the 
important apoprotein.  
• Intermediate density or broad beta lipoproteins. 
• Low density or beta lipoproteins. Major apoprotein is B-100. 
• High density or alpha lipoprotein. Major apoprotein is apo-A. 
 
Fig. 13. Lipoprotein Structure  
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Among the many technique used to separate lipoprotein, the following 
are important  
1. Ultracentrifugation  
There are two principle ways of using ultracentrifugation to determine 
lipoproteins. They employ two different instruments. The preparative and 
the analytical centrifuge. 
a) Preparative Ultracentrifugation: Plasma has a salt density of 
about 1.006. Ultracentrifugation of plasma without adjustment of 
its density for a short period brings the chylomicrons rapidly to the 
top of the tube. Longer ultracentrifugation at this density allows 
the VLDL to be collected on the surface. Addition of salt to plasma 
will further raise the density to selected levels and permit isolation 
of other lipoproteins. Those lipoproteins, which are separated 
below a density of 1.006 constitute VLDL, 1.006 to 1.063 
constitute LDL, 1.063 to 1.21 constitute HDL.  
b) Analytical Centrifugation: In this instrument, plasma fraction 
usually prepared at salt density of 1.063, is centrifuged at high 
speeds and the moving bands of the floating lipoproteins are 
photographed and later used to determine the concentration that are 
referred to certain standard conditions. 
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2. Electrophoresis: 
If the plasma is examined by paper or agarose gel electrophoresis at 
pH 8.6, it is possible to demonstrate, by means of fat stains, the existence of 
four bands. Three of these move towards the anode and one remains at the 
origin, that is, the line of application of the serum, the faster moving band 
occurs approximately in the same position as alpha-I globulin. It is known as 
alpha-lipoprotein and corresponds to the HDL fraction, demonstrated by 
ultracentrifugation floatation technique. The next band appears at 
approximately the position of beta globulin and is known as beta lipoprotein, 
which corresponds to LDL fraction. Another band appears between the 
position of alpha globulin and beta globulin. It is known as pre-beta 
lipoprotein, which corresponds to VLDL fraction. The band, which remains 
stationary at the origin, consists of the chylomicrons. The five principal 
lipoprotein classes are defined according to their density on 
ultracentrifugation and by their mobility on agarose gel electrophoresis. In 
addition, they can be classified on the basis of size and relative concentration 
of cholesterol or triglyceride and by their apoprotein content. 
Chylomicrons 
 
Chylomicrons are the largest of the lipoproteins. Their primary 
function is to transport dietary, or exogenous, triglycerides and cholesterol 
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from the intestinal lumen to the sites of metabolism or storage. The  
chylomicrons are formed in the gastrointestinal (GI) tract. In the lumen of 
the GI tract, dietary fat is degraded into free fatty acids and monoglycerides. 
These substances enter the intestinal villi, where they are reconstructed into 
a triglyceride particle. Dietary cholesterol absorbed into the intestinal wall is 
then esterified to cholesteryl esters, mainly cholesteryl oleate, by the 
enzymatic reaction catalyzed by cholesterol acyl transferase. The 
triglyceride and cholesteryl esters are then combined with apos beta-48, A-I 
and A-IV within the intestinal wall to form chylomicron particles. 
 
Fig. 14. Lipoprotein Separation Techniques 
The nascent chylomicrons enter the systemic circulation by the way 
of lymphatics. Apos E and C are then added to the particles. Normally, the 
chylomicrons are cleared rapidly from the blood and are virtually absent in 
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the fasting state. The clearing of the chylomicrons is modulated by the 
enzyme lipoprotein lipase (LPL). LPL catalyzes hydrolysis of the 
triglyceride core of the chylomicron, leaving a remnant particle rich in 
cholesterol, apo C, apo E, and apo B-48. During this process, apoproteins, 
phospholipids, and cholesterol from the surface of the chylomicron are 
transferred to HDL particles. The chylomicron remnants are cleared rapidly 
from the circulation by receptors present on the surface of liver cells. These 
receptors recognize the apo E component of the remnant particles. 
Remnants that contain the apo E2moiety bind less well, and are thus 
removed less quickly than remnants that contain either the apo E3 or E4 
moiety. 
Chylomicron remnants are thought to be atherogenic, and an 
abnormal delay in their clearance is therefore undesirable. Delay in 
chylomicron clearance may be secondary to a genetically inherited 
deficiency of LPL or its activator, apo C-II. It is partial degradation of the 
chylomicron to a remnant that renders the particle atherogenic. Delayed 
clearance of the remnant particles may damage the vascular endothelium, 
and thus predispose to atherosclerosis. 
 
Hyperchylomicronemia also may be secondary to other acquired 
hypertriglyceridemic states, such as those seen with exogenous estrogen 
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use, uncontrolled diabetes, and excessive alcohol intake. The presence of 
chylomicrons in the serum is necessary for the diagnosis of typeI or V 
hyperlipoproteinemia in the Fredricksons classification system. 
Very Low-Density Lipoprotein 
VLDLS are the intermediate in size between chylomicrons and IDLS. 
They are relatively large particles, with diameters ranging from 500 to 800 
A. VLDLS are produced in the liver. Their primary lipid component is 
triglyceride, but cholesterol, cholesterol ester, and phospholipid are also 
present. The synthesis of VLDL is increased by excess carbohydrate, 
alcohol, or caloric consumption. VLDL is used to take the cholesterol & 
TGL to the pen tissues & have fatty acids are utilized for energy & also 
stored as TGL. 
When VLDL particles enter the systemic circulation, their triglyceride 
core is hydrolyzed by LPL. As the VLDL particle is degraded, most of its 
surface apoproteins, except for apo B-100, are transferred with other surface 
components to HDL. The remaning VLDL remnant is called  IDL. Unlike 
the chylomicron remnant, IDL contains apo B-100 rather than pro B-48. The 
metabolism of VLDL is complex and not fully understood. Some of the 
larger particles appear to be directly removed from the circulation. The rest 
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of the particles enter the cascade, in which they are converted to IDL and 
eventually to LDL. 
INTERMEDIATE DENSITY LIPOPROTEIN 
 IDLs, which carry both cholesterol and triglyceride, are the products 
of the enzymatic (LPL-medicated) breakdown of VLDL. After their 
formation, IDLs may be removed by the liver by means of the binding of 
apo E to the IDL or B/E receptor. The remainders are converted to IDL, a 
process, thought to be mediated by hepatic triglyceride lipase. IDLs have 
high cholesterol content and migrate in the beta region on electrophoresis. 
Elevation of IDLs is thought to predispose to premature CAD and peripheral 
artery disease. Accumulation of IDL is characteristic of dysbeta 
lipoproteinemia, also called Fredrickson’s type III hyperlipoproteinemia. 
This relatively uncommon from hyperlipoproteinemia is associated with 
both triglyceride and cholesterol elevation.  
LOW DENSITY LIPOPROTEIN 
 LDL, which is 45 percent cholesterol by weight, is the major carrier of 
cholesterol to the nerve tissue, cell membranes and other cells that require 
the cholesterol for metabolic functions, including the synthesis of steroid 
hormones. LDLs have a density of 1.019 to 1.063 gm.ml a diameter of 180 
to 280 A, and beta electrophoretic mobility. LDL usually is formed from 
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VLDL breakdown. Direct synthesis has not been completely excluded. 
Increase LDL synthesis may occur be means of enhanced conversion of 
VLDL remnants or direct hepatic production of apo B containing 
lipoproteins. 
ApoB-I00 is the only protein found in LDL, and makes up about 20 
percent of the LDL mass. Each particle is thought to contain 1 molecule of 
apo B- 100, but the ratio of protein mass to total particle mass can vary from 
the large to the small particle range. LDL particles are heterogenous, 
differing in their hydrated density and cholesteryl ester in the LDL particle, 
for example, may vary upto 40 percent by weight. Patients with greater 
concentration of small, dense LDL, have been reported to have a three times 
greater risk for acute myocardial infarction (MI), regardless of weight or 
gender. Small, dense LDL molecules are commonly associated with male 
gender, diabetes, depressed HDL levels and familial combined 
hyperlipoproteinemia. 
LDL particles are recognized by specific  LDL  or  apo  B/E  receptors  
on  the surfaces of hepatic and certain non hepatic cells. These receptors also 
recognize and bind some of the apo E containing IDL particles, preventing 
their conversion into LDL. Bound LDL particles (and IDL particles) are then 
internalized into the cells. About 75 percent of the LDLs in the blood stream 
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are removed by this specific receptor mediated binding. The reminding LDL 
particles are cleared by scavenger or macrophage receptors or by non-
receptor mediated mechanism. The number of LDL receptors is not fixed, 
and can be modified by genetic defects, saturated fat and cholesterol intake 
or certain pharmacological agents. 
The prototype disease involving the LDL receptor is familial 
hypercholesterolemia. In this condition, heterozygotes have  a 50 percent 
reduction in LDL receptors, where as homozygotes have little or no receptor 
activity. Familial hypercholesterolemia is fairly common, occurring in 1 in 
every 500 people. Familial combined hyperlipidemia (FCH) is even more 
common, possibly occurring in 1 in every 500 people. Clinically, FCH 
patients may be difficult to differentiate from those with familial 
hypercholesterolemia. In FCH, most patients lack tendon xanthomas; most 
family studies show varying Fredrickson's phenotypes. 
The characteristic defect in FCH is thought to be an overproduction of 
apo B- 100 by the liver. Also, FCH patients have a lower ratio of apoA-I to 
apoB-100. About 80 percent of patients with an elevated LDL value do not 
have only one gene defect; the dyslipidemia is secondary to polygenic 
factors. Hence, elevations of LDL due to primary receptor defects are 
relatively uncommon. 
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Fredrickson Classification of the Hyperlipidemia 
Table: 2 
Fredrickson Classification of the Hyperlipidemia 
 
Phenotype Lipoprotein Abnormality Result 
Type I Chylomicrons elevated Very high TG 
Type IIa LDL elevated High cholesterol 
Type IIb LDL and VLDL elevated High cholesterol and TG 
Type III IDL elevated High cholesterol and TG 
Type IV VLDL elevated High TG, normal to slightly high 
cholesterol 
Type V Chylomicrons present and 
VLDL elevated 
Very high TG and cholesterol  
 
High Density Lipoprotein 
HDLs are produced by the liver and the GI tract and by the peripheral 
catabolism of chylomicrons and VLDLs. HDL particles carry cholesteryl 
ester as their major lipid and apos A-I and A-II as their major proteins. Much 
of the apoprotein component of HDL is transferred in the systemic 
circulation to VLDLs or chylomicrons. Apo C-II an obligatory activator of 
LPL, is one of the apo proteins transferred by HDL. By weight, HDL 
particles are about 30 percent cholesterol, 45 percent protein, and 25 percent 
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phospholipid (predominantly phophatidyl choline). Small amounts of 
triglycerides are present. 
HDL particles exist in several subtypes. For clinical purposes, HDL2 
and HDL3 are the major circulating subfractions. HDL2, which migrates 
with alpha mobility, is the subfraction, most closely associated with 
statistical protections against premature atherosclerosis. It has a density of 
1.061 to 1.201 gm/ml and a diameter of 90 to 120A. HDL3 is a smaller 
particle, with a density of 1.125 to 1.210 gm/ml and a diameter of 50 to 90A. 
Alcohol consumption increases both HDL subfractions, with a greater 
impact on HDL3. Lower levels of both subfractions are associated with male 
gender, hypertriglyceridemia, diabetes mellitus, obesity, uremia, the use of 
androgens, progestins, and tobacco products; and diets rich in 
polyunsaturated fats but low in total fat content. 
Several epidemiological studies have addressed the debate whether 
there is a varying clinical impact on CAD depending on the relative levels of 
HDL2 and HDL3. In males with CAD who have an associated low level of 
circulating HDL, both fractions of HDL are depressed with more of a 
decline in HDL2. 
HDL particles are thought to participate in the reverse transport of 
free cholesterol from peripheral tissues by way of a putative HDL receptor. 
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Oram and co-workers report that apos A-I and A-II interact with this  
receptor.  This receptor mediated reverse transport could explain why 
patients with elevated HDL concentrations are less prone to CAD. 
Another explanation for the inverse relation between HDL levels and 
CAD incidence may be related to the observation that most patients with low 
levels of HDL have elevated levels of the more cholesterol and triglyceride 
rich lipoproteins. In this case, Low HDL levels may serve only as a marker 
for other, concurrent lipid abnormalities. 
Just as low levels of HDL are statistically associated with 
atherosclerosis, HDL is increased on a genetic basis in familial hyper 
apolipoproteinemia. The condition has been described as being associated 
with longevity. 
 
Fig.15. Comparison of density and diameter of lipoproteins 
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Lipoprotein (A) 
Lipoprotein(a), or Lp(a), has been established as an independent CAD 
risk factor. The structure of Lp(a) is similar to that of an LDL molecule 
linked by a disulfide bridge to apoprotein(a). It has a density of l.085gm/ml 
and a size of 25A and it migrates in the pre beta region. Lp (a) levels range 
from l mg/dl to 100 mg/dl, with the largest number of values below 
20mg/dl. 
Although Lp(a) is structurally similar to LDL, the former appears to 
be regulated independently and carries an independent relation to overall 
coronary risk. If serum levels of both LDL and Lp(a) are elevated, the risk 
of CAD is  markedly increased. Recent angiographic studies have 
documented a positive correlation between Lp(a) levels and the severity of 
coronary atherosclerosis. 
The mechanism by which high levels of Lp(a) are related to coronary 
atherosclerosis is unclear. It has been suggested that because of the structural 
similarities of Lp(a) to plasminogen, high levels of Lp (a) may inhibit the 
thrombolytic activity of naturally occurring tissue plasminogen activity. 
Plasminogen is composed of five sequences of aminoacids rich in cysteine. 
Each sequence is called a kringel. Lp(a) lacks the first three kringles, but has 
a sequence that is highly homologous to the fourth kringle of plasminogen. 
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This particular sequence is repeated 37 times in the Lp(a) molecule. There is 
no serine protease activity in Lp (a) and no thrombolytic activity. An 
alternate explanation for the association between elevated Lp(a) levels and 
atherosclerosis is that Lp(a) may some how alter the LDL mediated delivery 
of cholesterol to the atherosclerotic plaque. 
The control mechanisms of Lp (a) are unknown. Dietary changes that 
increase LDL levels do not affect Lp (a) levels. The effects of 
pharmacological agents are unclear, although Lp (a) has been reported to be 
decreased by niacin, neomycin, and stanozolol. 
Lipids and Atherosclerosis 
It is well established that hypercholesterolemia due to elevated blood 
levels of LDL is a major cause of CHD and that lowering elevated levels of 
cholesterol will reduce the risk of coronary disease. Inverse relationship is 
noted with HDL.  There is also a weak correlation between plasma 
triglycerides and the incidence of coronary artery disease. The exact 
mechanism of atherogenesis is still in controversy. LDL particles which get 
oxidized (by natural process) may be particularly atherogenic. Receptors on 
the surface of macrophages within the plaque, binds and accumulates 
oxidized LDL. The formation of antibodies to oxidized LDL is also 
important in plaque formation. There is a possibility that chronic 
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hyperlipidemia may initiate endothelial injury which stimulates 
atherosclerosis. This injury favors adherence of monocytes and lymphocytes 
at the focus of injury, in part owing to the stimulation of endothelial cell 
synthesis of adhesion molecules. It induces a change in the platelet 
membrane composition leading to activation and increased adhesiveness of 
platelets. With chronic hyperlipidemia, lipoproteins accumulate within the 
intima at sites of endothelial injury or dysfunction. 
 
Fig. 16: Atherogenesis 
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A strong negative correlation has been demonstrated between plasma 
levels of HDL cholesterol and CHD. Most of the variability in HDL 
cholesterol levels reflect HDL2 levels; plasma levels of the other major HDL 
subclass, HDL3, are fairly constant both intra and inter-individually. 
HDL particles secreted into the circulation by liver and cholesteryl 
ester enriched macrophages   are   complexes   of   apolipoproteins   and   
phospholipids   and   acquire unesterified cholesterol originating in cell 
membranes during cell renewal or death. Their major phospholipid is 
phosphatidyl choline or lecithin. 
Both lecithin and unesterified cholesterol serve as substrates for the 
cholesterol- esterifying enzyme, lecithin cholesterol acyltransferase (LCA 
T), which circulates with HDL in the plasma. LCAT acts on the nascent 
HDL particles to generate a core of cholesteryl esters and to change the 
structural transition to mature, spherical HDL particles. LCAT also acts on 
mature HDL3 particles, i.e., after they have acquired cholesterol and lecithin 
not only from cell membranes but also from chylomicrons and VLDLs 
during lipolysis of those particles. Generation of cholesteryl esters by the 
LCAT reaction leads to enlargement of the small HDL3 particles such that 
they are converted into the larger HDL2 particles. Formation of HDL2 
increases the cholesterol-carrying capacity of HDL, and HDL cholesterol 
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levels raise, this drives the process termed “reverse cholesterol transport”, in 
which HDL returns cholesterol from peripheral tissues to the liver for 
excretion into the bile. 
The cholesterol esters of HDL, particularly of HDL2 formed de novo 
by the LCAT action, need not remain within the HDL core. They can be 
transferred from HDL to the triglyceride rich lipoproteins, i.e., chylomicrons 
and VLDL in exchange for triglyceride molecules. This hetero exchange of 
insoluble cholestery lesters and triglycerides between HDL and triglyceride 
rich lipoproteins is catalyzed by the action of cholesterol ester transfer 
protein. 
The transferred triglycerides are hydrolyzed from the HDL core by 
hepatic lipase, located in the endothelial cells of the liver. Only cholesteryl 
esters those that were not exchanged for triglycerides remain in the core. 
Hence HDL2 particles are converted back into the smaller HDL3 particles. 
This mechanism is the basis for the well-established clinical observation 
that, individuals with permanent or temporary hypertriglyceridemia (due to 
increased levels of VLDL or due to accumulation of chylomicrons in the 
course of postprandial lipemia) have low HDL2and low HDL cholesterol 
levels. 
The cholesteryl esters transferred from HDL and the triglyceride rich 
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lipoproteins remain with the latter particles along their lipolytic cascades and  
the  endocytotic pathways of their remnants (i.e., the LDL receptor and the 
scavenger pathways). Thus, transfer of cholesteryl esters from HDL to 
triglyceride rich lipoproteins may contribute to the atherogenic potential of 
chylomicrons and VLDL, in that “good” cholesterol is turned into “bad” 
cholesterol. 
Although there is no clinical trial directly demonstrating the benefit of 
increasing HDL cholesterol alone, Helsinki Heart Study results suggests that 
increasing HDL add benefit to lowering LDL in CHD risk reduction. 
Similarly, data from the Prospective Cardiovascular Muenster (PROCAM) 
Study have shown that the combination of LDL elevation, 
hypertriglyceridemia, and low HDL confers greater risk of CHD than 
elevated LDL alone. 
There are several causes for low serum HDL cholesterol levels. Heavy 
cigarette smoking is a documented cause. Obesity is an apparent association, 
as is a sedentary lifestyle. Hypertriglyceridemia is frequently associated with 
very low HDL levels. Certain drugs can also have an appreciable depressing 
effect on HDL. Finally, there is evidence that isolated low HDL cholesterol, 
termed hypoalphalipoproteinemia, may be genetically transmitted in an 
autosomal dominant fashion. Patients with this disorder have a normal lipid 
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profile other than the low HDL but an apparently increased risk for 
atherosclerosis. 
There commended methods for improving HDL cholesterol values are 
non- pharmacologic; smoking cessation, weight reduction, regular and 
vigorous exercise and alteration of offending drugs, if possible. As yet, there 
is no direct evidence that drug- induced increases of low HDL cholesterol in 
the setting of normal LDL cholesterol and triglyceride levels are beneficial 
in CHD risk reduction. HDL cholesterol levels can be increased with 
gemfibrozil (the agent used in the Helsinki study) or nicotinic acid. 
The possibility that chronic hyperlipidemia, and particularly 
hypercholesterolemia, may itself initiate endothelial  injury  has  enticed  
many investigators. Much evidence suggests that hypercholesterolemia has a 
variety of adverse effects. 
It increases the cholesterol- phospholipid ratio of endothelial cell 
membranes, rendering them more rigid and less able to maintain their 
normal intercellular associations, potentially increasing permeability and in 
effect causing a subtle form of endothelial injury. 
It favours the adherence of monocytes and lymphocytes to the focus 
of injury, in part owing to the stimulation of endothelial cell synthesis of 
adhesion molecules. 
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It induces changes in platelet membrane composition, leading to 
activation and increased adhesiveness of platelets. 
With chronic hyperlipidemia, lipoproteins accumulate within the 
intima at the site of endothelial injury or dysfunction. Although significant 
amounts may enter the arterial wall, there is some concurrent efflux, perhaps 
mediated by HDL. 
Most important, it provides the opportunity for oxidation of 
lipoproteins, yielding modified LDL. 
	  
Fig. 17: Stages of atherosclerosis 	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Apoproteins 
Apoproteins are key lipoprotein components that serve both as 
enzymatic co- factors and as recognition elements that bind to specific 
receptors on peripheral tissues, including the vascular endothelial cells. It is 
the apo E component of the chylomicron remnant, for example, that is 
recognized by receptors on the hepatocyte. The apoproteins are distinguished 
alphabetically and numerically as apo A-I through apo E. 
A great deal of research has been conducted in the use of apoproteins 
as CAD markers. Some investigators have found that the concentration of 
apo A-I and apo B-100 are better predictors of CAD than are measurements 
of total plasma lipids or lipoproteins. In one study, apo A-I was the best 
predictor of atherosclerotic risk in patients undergoing coronary 
arteriography. In this study, higher levels of apo A-I were associated with a 
deceased prevalence of obstructive coronary lesions. Indeed, apo A-I was 
found to be a better CAD predictor than either total cholesterol or HDL. 	  
Apoprotein A 
 
Apo A-I, the prototype of apo A, is a major protein in HDL and also is 
seen in chylomicrons. It has a molecular weight of 28,000 and is synthesized 
in the GI tract and liver. Its specific regions called amphipathic helices are 
enriched with charged amino acids that form areas of polar and non-polar 
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residues. Apo A-I functions as the activator of lecithin cholesterol acyl 
transferase (LCAT), and also has been found as a degradation product in 
amyloid fibrils. 
Apo A-II is a minor constituent of HDL and does not appear to be 
present in all species. Human apo A-II is of hepatic origin and consists of 
two identical chains attached by a single disulfide linkage. Apo A-II may be 
an activator triglyceride and phospholipid while utilizing HDL2 as its 
preferred substrate. Apo A-IV is synthesized in the gut and is present in 
HDL, chylomicrons and as a free protein. Its molecular weight is 46,000, 
and its structure is helical. Although its function is not known, it also may be 
an activator of LCAT. 
The genetic codes for apos A-I, A-IV and C-III are close together on 
the long arm chromosome 11.Combined A-I/C-III deficiency are associated 
with severe premature atherosclerosis.  
Apoprotein B 
 
Apo B occurs in two forms. Apo B-48 is synthesized by the small 
intestine, and apo B-100 is secreted by the liver. Apo B-48 is present on 
the surface of chylomicrons and chylomicron remnants. Apo B-100 is 
found in VLDL, IDL and LDL. Apo B-I00 is the primary apoprotein of 
LDL and accounts for 25 percent of its weight. It also is the recognition site 
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for the LDL or apo B/E receptor on cell surfaces. It has recently been 
determined that a single gene regulates the synthesis of both apo B-48 and 
apo B-100. The gene for apo B-I00 has been localized to chromosome 2 and 
exists as a 40 kilobase structure. The structure in the amino acid sequence of 
human apo B-100 and the corresponding cDNA messenger have recently 
been determined. A unique editing mechanism introduces a stop codon into 
the mRNA for apo B by means of a single base change. This allows the 
biosynthesis of two proteins from a single gene and mRNA, with either apo 
B-1 00 or apo B-48 being synthesized. 
Apoprotein E 
Most apo E is synthesized in the liver. However, other tissues, 
including the small bowel, kidney, adrenals, and the cells of the 
reticuloendothelial system, have the ability to synthesize this apoprotein. 
Apo E accounts for about 15 percent of the protein content of VLDL, 7 
percent of the protein content of chylomicron remnants and 2 percent of the 
protein content of HDL. It can be recognized by the LDL or apo B/E 
receptor and by specific apo E receptors in the liver whose function appears 
to be the removal of chylomicron remnants. Apo E is polymorphic and 
contains three major alleles; apos E2, E3, and E4. These respective alleles 
are present in about 10 percent, 76 percent, and 13 percent of whites. Their 
	  61	  
various combinations result in homozygtes for apos E2/2, E4/4. 
Also, apos   E2/3, E2/4   and   E3/4   exist   in   the   heterozygous 
state.   The polymorphism of apo E has been determined on a molecular 
basis and results from the substitution of an amino acid at residues 112 and 
158 in the protein. About 90 percent of the patients with type III 
hyperlipoproteinema (HLP) are homozygous for the E2/2 phenotype. This 
disorder is characterized by hypercholesterolemia, hypertriglyceridemia and 
IDL or VLDL particles abnormally enriched in cholesterol. These particles 
have beta electrophoretic mobility and are termed beta-VLDLs. Premature 
coronary and peripheral vascular disease is characteristically associated 
with type III HLP. Type III HLP is also by the delayed clearance of 
chylomicron remnants in the serum due to impaired binding of these 
remnants to the lipoprotein receptors in isolated cells. Because the E2/2 
genotype occurs in 1 percent of the population, and type III HLP is rare, a 
second abnormality must be present. 
Apo E isoforms may account for as much as 15 percent of the 
variability of cholesterol and LDL levels in the population. Also, recent 
Finnish studies suggest that E4 may be associated with increased cholesterol 
absorption in the GI tract. In the Prospective Cardiovascular Muenster 
(PROCAM) study, E2 was associated with lower cholesterol levels and E3 
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or E4 with higher levels of total cholesterol and LDL, in populations with 
and without CAD. 
Table: 2 
SUMMARY OF APOPROTEINS 
NAME LIPOPROTEIN FUNCTION 
Apo A-I HDL, Chylomicrons Structural; activator of 
LCAT enzyme 
Apo A-II HDL, Chylomicrons Structural 
Apo A-IV HDL, Chylomicrons, VLDL Unknown  
Apo B-IOO LDL, VLDL Structural; Synthesis and 
secretions of VLDL; bind to 
LDL receptors (B/E) 
Apo B-48 Chylomicrons Structural; Synthesis and 
secretion from intestine 
Apo C-I HDL, Chylomicrons, VLDL Activator of LCAT 
Apo C-II HDL, Chylomicrons, VLDL Activator of Lipoprotein 
lipase 
Apo C-III HDL, Chylomicrons, VLDL Stabilizes surface; provides 
negative charges 
Apo D HDL, Chylomicrons Cholesterol ester exchange 
Apo E HDL, VLDL, Chylomicrons Binds to receptor on cell 
membrane of liver (E and 
B/E) and macrophage. 
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SMOKING AND CORONARY HEART DISEASE 
Coronary heart disease is common in both the developed countries 
and developing countries. It is estimated that approximately 1.5 million 
infarcts occur in USA alone. Hyperlipidemia a major risk factor for 
atherosclerosis is characterized by raised levels of lipids (triglyceride 
cholesterol) and lipoproteins (low density lipoproteins) and very low-density 
lipoproteins. These factors vary among various socioeconomic states. 
Cholesterol was postulated to be related to atherosclerosis when it was 
found to be a major component of advanced atherosclerotic plaques. The 
association between elevated serum cholesterol and atherosclerotic disease 
was first reported in 1930. Subsequent large epidemiologic studies such as 
the seven countries study and the Framingham heart study confirmed the 
relationship between serum cholesterol and CAD. In the multiple risk factor 
intervention trial (MRFIT), the relationship between serum cholesterol level 
and subsequent CAD was found to be continuous, graded and strong. 
The lipid research clinics prevalence study demonstrated, in a 10-year 
follow up, that low-density lipoprotein cholesterol was strongly associated 
with CAD death in men with or without CAD. 
In John Hopkins precursors study, cholesterol levels determined in 
young men in their early twenties were predictive of risk of developing 
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CAD 3-4 decades later. The concept of plaque stabilization in which 
cholesterol reduction alters vulnerable plaque in a way that may not 
substantially change its angiographic stenosis is not well understood. It is 
thought to be due to lipid depletion of the lesion core, stabilization of 
endothelium, inhibition of platelets or effects on vascular smooth muscle 
cells. Helsinki heart study has shown reduced cardiovascular mortality with 
cholesterol reduction. 
Cigarette smoking acts both independently and synergistically with 
other risk factors like hypertension and hypercholesterolemia.  Mortality 
from coronary heart disease is substantially higher in cigarette smokers than 
non-smokers. It is generally believed that harmful cardiovascular effects of 
smoking are partly caused by changes in lipid metabolism. 
Gofman JW et al, pioneers in the study of the relationship of smoking, 
serum lipoproteins and heart diseases found a strong relationship between 
themselves as well as with coronary artery disease. 
According to the studies of Albany and Framingham, the incidence of 
myocardial infarction in heavy smokers is three times more than in non- 
smokers. In Framingham offspring study, Wilson PW, Anderion KM et al 
studied patients from 1972-1974. The patients being the off springs of the 
original participants in the Framingham Heart Study, they underwent a 
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baseline examination for standard cardiovascular risk factor. The off springs 
were 30-59 years old and free of coronary heart disease. They were 
followed for 12 years during which time 156 out of 1663 men and 55 out of 
1714 women developed CHD. The result of that multivariate proportional 
hazard model was that, coronary heart disease is significantly related to age, 
reduced HDL and the amount and duration of tobacco smoking. Blood sugar 
levels and LDL values were strongly related with coronary heart disease in 
males, but less significantly in f e m a l e s , while triglycerides and VLDL 
were not associated with coronary heart disease after adjustment for high 
density lipoprotein cholesterol and glucose. 
Castelli WP et al, who reviewed with the Framingham study on 
coronary heart disease have shown that life style, particularly diet, smoking 
and alcohol consumption have a great impact on the incidence of coronary 
heart disease. Blood lipoproteins, rather than total cholesterol have been 
found to be more accurate predictors of coronary heart disease. Blood 
triglycerides previously considered to have little bearing on a coronary heart 
disease risk was found to have a negative impact in many cases. 
Knutsen SF et al in Tromso Heart Study on the risk for coronary heart 
disease in wives of coronary high risk men found a significantly higher 
total cholesterol ratio, higher body mass index and higher coronary risk 
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scores compared to the age matched married women in general population. 
Furthermore, higher proportions of these individuals were daily cigarette 
smokers and had received fewer years of education. The members of the 
same household of a person with an increased risk for CHD also had 
increased risk, probably due to shared life style. 
In a study of all patients admitted to the coronary care unit of 
St. Vincent's Hospital in Dublin, Ireland, which numbered 978 with a first 
documented myocardial infarction, a study was made to detect smoking 
related differences in clinical profile and in hospital outcome. The 
distribution of infarct size differed significantly between smokers and non-
smokers. Smokers had a higher cardiac enzyme concentration. The study 
was conducted between 1980-85. Tomono, Sand Ohshima S reviewed the 
histories and laboratory data of 67 young patients with ischemic heart 
disease under the age of 40 years. The risk factor in 13 of them was heavy 
smoking. But it came second to hypercholesterolemia patients, who number 
23. The results indicated that hypercholesterolemia is the most important 
risk factor for ischemic heart disease in young patients, although other 
accepted risk factors like hypertension, diabetes and cigarette smoking were 
associated with the development of the disease. 
Fujiwara et al, conducted a study, to assess the metabolic risk factor in 
	  67	  
normolipidemic patient with angiographically defined CHD.  In the CAD 
group cumulative lifetime tobacco consumption was higher and HDL 
cholesterol concentration was lower than that in those without coronary 
artery disease group. 
Smoking accelerates myocardial infarction not only by accelerated 
development of atherosclerosis but also by augmenting the existing 
thrombotic and vasospastic effect. The arrythmogenic effects of smoking 
increases the risk of threatening arrhythmias and sudden cardiac death and 
myocardial infarction occurred in young smokers with nearly normal or 
normal coronary arteries.  Smokers who undergo coronary artery bypass 
surgery have increased perioperative mortality compared to non-smokers. 
Cigarette smoking may produce an imbalance between myocardial O2 
demand and supply. 
SMOKING AND PERIPHERAL ARTERIAL DISEASE: 
Peripheral arterial disease (PAD) in most of the developed countries is 
due to atherosclerosis and so tobacco smoking is strongly associated with 
PAD. Most of the serious manifestations of PAD are due to rupture of the 
plaques. In UK about 25% of the middle aged persons are having PAD. But 
only one fourth of them are having the symptoms. The manifestations vary 
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according to the site of involvement, presence of collateral supply, speed of 
onset and mechanism of injury. 
CHRONIC LOWER LIMB ARTERIAL DISEASE: 
PAD affects the lower limbs more often than the upper limbs(around 
8 times more).  
The presentation of leg ischemia may be as: 
1. Intermittent claudication (IC) 
2. Critical limb ischemia (CLI) 
The severity of limb ischemia is assessed by 
1. Clinical examination 
2. ABPI (ankle brachial pressure index) – is the ratio between highest 
systolic ankle and brachial blood pressure. 
a. Normal>1.0 
b. I.C- 0.5-0.9 
c. C.L.I. <0.5 
INTERMITTENT CLAUDICATION: 
It is the pain in the muscles of leg which occurs while walking, and is 
due to ischemia. As the superficial femoral artery is the one which is 
commonly involved, the pain is commonly present in the calf muscles. If the 
disease involves iliac arteries the pain occurs in the buttock or thigh muscles. 
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Normally the pain occurs after a particular claudication distance. When 
walking is stopped the pain gets subsided immediately. Then the pain recurs 
when walking is resumed. Due to progression of the disease and 
development of collateral blood supply, mostly the patients will be 
experiencing a cyclical pattern of exacerbation and then resolution of 
symptoms. 
Around 4.5% of men in middle age will experience intermittent 
claudication. If the patients comply well with medical management, only 
0.5-2% will deteriorate and go for amputation or revascularization. But the 
annual mortality in these patients is more than 6%, which is 3 times more 
than the non-claudication population. Because this claudication pain is 
almost always associated with diffuse atherosclerosis, these patients face 
death due stroke or myocardial infarction. 
The best medical therapy includes mainly supervised exercise therapy. 
The use of peripheral vasodilators improves the distance of walking. Other 
interventional procedures are: 
1. Stenting 
2. Endarterectomy 
3. Angioplasty 
4. Bypass surgeries 
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These procedures are considered in patients who are disabled severely 
and not improved symptomatically even after 6 months of best medical 
therapy. 
CRITICAL LIMB ISCHEMIA: 
• Rest or night pain will be present. 
• Associated with loss of tissue (gangrene or ulceration). 
• Persisting > 2 weeks. 
• With ankle B.P. of less than 50mmhg 
  SUBCRITICAL LIMB ISCHEMIA: 
• Only rest pain is present 
• Ankle B.P. more than 50mmhg 
Severe limb ischemia includes both critical and subclinical limb 
ischemia. In intermittent claudication plaque will be present in a single 
segment only.  In severe limb ischemia plaque will be present in multiple 
levels. These patients with severe limb ischemia are at higher risk of losing 
limb when compared to those with intermittent claudication. But treatment 
in these patients is difficult as they almost have extensive end stage disease 
and they also have associated multisystem involvement by atherosclerosis. 
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BUERGERS DISEASE: 
 This is an inflammatory obliterative arterial disease. It usually affects 
male smokers of young age. It typically involves distal arteries and present 
with claudication of feet and rest pain of fingers. Pulses are absent in wrist 
and ankle but present in brachial and popliteal vessels. Superficial 
thrombophlebitis also occurs as the disease involves veins. The disease 
mostly remits on cessation of tobacco smoking. If these patients don’t stop 
smoking, the disease progresses to the level of amputation. Prostaglandin 
infusions and sympathectomy might be useful. 
SMOKING AND RESPIRATORY DISEASES: 
89% of chronic obstructive pulmonary disease is due to tobacco 
smoking. Within first few years of starting smoking, the smokers manifest 
inflammatory changes in their smaller airways. But lung function tests 
during this period wont predict the evolution to chronic airflow limitation. In 
chronic smokers pathophysiologic changes start developing after 2 decades 
and these changes in lung progress depending on the time duration and 
severity of smoking. More than 70% of the smokers will be having a 
productive cough due to the presence of chronic mucous hyperplasia in large 
airways. Narrowing of the smaller airways due to chronic inflammation and 
enzymatic degradation of walls of alveoli leads to emphysema. This 
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produces expiratory airflow limitation, which leads to clinical symptoms in 
around 22% of smokers. In smokers of young age group small airway related 
changes gets reversed within one to two years of smoking cessation. A small 
improvement in expiratory airflow changes is observed in smokers who have 
developed chronic airflow limitation after smoking cessation. But the 
important change after cessation is deceleration of declining lung function 
rather than returning to normal. 
SMOKING AND CANCERS: 
Smoking is associated with cancers of oropharynx, nasopharynx, 
hypopharynx, oral cavity, larynx and lungs. It is also associated with cancers 
of oesophagus, stomach, pancreas, body and pelvis of kidney, urinary 
bladder, ureters, and cervix. It also increases the risk of leukemias of 
myeloid series. There is also increased risk of developing hepatoma, breast 
cancer (premenopausal), and colorectal cancers. It is not found to be related 
with postmenopausal breast cancers. In postmenopausal smokers there is a 
reduced risk of developing cancers of endometrium. There is a synergesic 
effect of alcohol with smoking in the development of malignancies of 
oesophagus, oral cavity and lung. Occupational exposures like radon and 
asbestos act synergistically with tobacco to increase the risk of developing 
cancers of lung. Smoking cessation produces a reduced risk of smoking 
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related malignancies. But even after 2 decades of stopping smoking there is 
modest increased risk of lung malignancies.  
SMOKING AND PREGNANCY: 
The maternal problems related to smoking are increased spontaneous 
abortions, placenta previa, placental abruption and increased risk of 
premature rupture of membranes. Infant related problems are preterm 
delivery, small for gestational age, increased perinatal mortality and 
increased risk of respiratory distress syndrome. These children will 
experience a developmental delay in the first few years of their life. 
OTHER CONDITIONS ASSOCIATED WITH SMOKING: 
• Osteoporosis 
• Senile cataracts 
• Peptic ulcers 
• Premature menopause 
• Macular degeneration 
• Skin wrinkling 
• Male impotence 
• Cholecystitis in women 
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• Gall stones 
ENVIRONMENTAL TOBACCO SMOKE: 
Non-smokers who have prolonged exposure to environmental tobacco 
smoke are at increased risk of developing coronary artery disease and lung 
cancers. Among children there is increased risk of bronchial asthma, chronic 
otitis media, and respiratory infections. There is also increased risk of 
premenopausal breast cancer. 
CESSATION OF SMOKING: 
• More than 75% of smokers like to stop smoking. 
• Every year 1/3rd of smokers try to quit the habit. 
• About 85% of the unassisted attempts to quit fail. 
• The process of cessation is a cyclical one that is, the person tries to 
quit smoking several times and fails repeatedly before succeeding 
finally. 
• Interventions for quitting smoking should be clinician based & the 
smokers should be encouraged to try quitting. 
• Rather than advising abrupt cessation in the first visit, various forms 
of cessation assistance should be advised with each new attempt to 
quit smoking. 
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• If the advice to quit smoking is given by the physician at the time of 
any acute illness it will be a strong trigger, and thereby most of the 
persons will make an effort to stop smoking. 
• Various nicotine replacement products are available. They are: 
o Nicotine gums 
o Nicotine lozenges 
o Nicotine patches 
o Nicotine oral inhalers 
o Nicotine nasal inhalers 
• The products can be used up to 6 months. 
• Antidepressant- Bupropion is found to be effective. 
• A partial agonist of nicotinic acetylcholine receptor, varenicline is 
also found to be effective. Psychiatric symptoms like suicidal 
ideations are found to be associated with the use of this drug. 
• Two weeks before the planned quitting date pretreatment with 
varenicline or antidepressants is adviced. 
• Nicotine replacement products can also be used in pretreatment. For 
more intense smokers higher doses are advised. 
• In patients who failed first line treatment, nortriptyline or clonidine 
may be useful. 
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• A combined approach with advice, counseling and pharmacological 
assistance mostly makes the cessation successful. 
PREVENTION OF SMOKING: 
• Most of the smokers start this habit in their teen age. The reasons 
behind this are: 
o Parental cigarette smoking. 
o Advertising and promotional activities for smoking tobacco. 
o Easy availability of cigarettes. 
o Acceptability of smoking by the society. 
o Adult imitating behavior and need for enhanced self image. 
• So prevention: 
o Must be started earlier even in primary school years. 
o Physicians treating teen agers should enquire about this habit 
and explain them the fact that most adults and adolescents don’t 
smoke. 
o Physicians should explain them the harmful effects and additive 
nature of tobacco in all forms. 
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4. METHODOLOGY 
This study was conducted among 200 patients who attended 
Government Rajaji hospital, Madurai.,  out patient department for various 
ailments between July 2014 to September 2014. 
INCLUSION CRITERIA: 
1. Age: 20-50 years 
2. 100 males who never smoked. 
3. 100 males smoking for 5 or more years, divided into three groups 
depending on intensity of smoking as follows   
a. Mild Smokers (1 – 10 Cigarettes / Bidis per day) 
b. Moderate Smokers (11 – 20 Cigarettes / Bidis per day) 
c. Severe Smokers (> 20 Cigarettes / Bidis per day) 
EXCLUSION CRITERIA: 
1. Obese 
2. Those on diet restriction. 
3. Those on drugs known to alter lipid profile. 
4. Those with history of alcohol intake. 
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5. Those with diseases known to alter lipid profile like diabetes mellitus, 
6. Hypothyroidism, renal failure. 
7. Those with hypertension and coronary artery disease. 
8. Those with family history of dyslipidemia. 
Since smoking is less prevalent among women in our country this 
study was conducted only in men. 
Blood Sampling and Laboratory Evaluation 
 The blood samples for analysis were taken at least after minimum of 
12 hours of complete fasting. The subject were asked to have a light, fat free 
diet on the day prior to sampling. 
 The venepuncture was done in the cubital fossa, Tourniquet was used 
but was released just before sampling to avoid artifactual increase in the 
concentration of serum lipids. 
 About 10 ml blood was drawn using perfectly dry and sterile 
disposable syringes. The serum was separated within 2 hours of collection to 
prevent artifactual changes in concentration of HDL. The sample were 
analyzed the same day or within 48 hours. 
 The lipid and lipoprotein assay was done using the Dr. Lange LP 700 
equipment. 
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Description of the Laboratory System LP 700: (Dr Lange) 
The laboratory system LT 700 consist of the following single instruments: 
• LP 700 Photometer (1) 
• LQV 016 Universal Thermostat (2) 
• LTV 015 Cuvette changer (Rack) Thermostat (3) 
• LQV 018 Suction Device (4) 
The filters of the wavelengths 340 nm, 405 nm, 492 mm, 546 nm, 578 
nm belong to the LP 700 and are automatically recognized by it. The 
following standard wavelengths 520 nm, 623 nm and 800 nm are available 
additionally.  
The cuvette compartment accepts any 10 mm square cuvette as well 
as the Dr. Lange Cuvette Test. 
The minimum volumes are: 
• 500 micro liter for SM square cuvette and  
• 450 micro liter for SM Suction cuvette  
• The filling volume of the Dr. Lange Cuvette Test is prefixed. 
The methods adopted for estimating the various lipid fraction is as follows: 
1) Serum cholesterol Estimation: 
This was done on a method based on CHOD-PAP method 
(Boehringer Mannheimn GmbH diagnostic catalogue No. 237574). 
	  80	  
Method: Enzymatic colorimetric method. 
Test Principle: 
 Cholesterol esterase (CHE) hydrolyses cholesterol ester. Free 
cholesterol is oxidized by the cholesterol oxidase (CHO) to Cholest-4-En-3-
one and hydrogen peroxide. Hydrogen peroxide formed reacts with 4-amino 
antipytine and phenol in the presence of peroxidase (POD) to produce pin 
colored dye.  
 
  Cholesterol+02
Cholesteroloxidase⎯ →⎯⎯⎯⎯⎯ cholest − 4− en − 3− one + H2O2  
 
2H2O2 + 4− a minophenazone+ phenol
peroxide⎯ →⎯⎯ 4− (P − benzoquinone −
monoimino)− Phenazone + 4H2O2
 
 Normal cholesterol value in serum: 150-240 mg/dI  
2) Serum Triglyceride Estimation: 
Triglyceride concentrations were determined by enzymatic 
colorimetric test (Boehringer Mannheim GmbH Cat. No. 701882) as per the 
details shown in the system specific working instructions supplied with the 
kits. 
Method: 
 Enzymatic hydrolysis of triglycerides with subsequent determination 
of the liberated glycerol by colorimetry 
 Cholesterol esters +H2O
Cholesterolesterase⎯ →⎯⎯⎯⎯ cholesterol+RCOOH
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Test Principle: 
 Triglycerides are hydrolyzed by lipase to glycerol and free fatty acids. 
Glycerol is phosphorylated by ATP in the presence of glycerol kinase to 
glycerol phosphate (G-3-P) which is oxidized by the enzyme glycerol 3-
phosphate oxidase (G-P-O) producing hydrogen peroxide. Hydrogen 
peroxide so formed reacts with 4-aminoantipytine/3, 5 dichloro-2-hydroxy 
benzene sulfuric acid to give a red colored complex which is read at 510nm 
(500- 50 nm) 
 
 
 
 
Clinical Interpretation: 
 Normal range: 74-172 mg% 
3) HDL Cholesterol Estimation: 
This involves two steps-precipitation and cholesterol estimation of the 
HDL – fraction by a modification of the method described by Burstein et al.  
Test Principle: 
 Triglycerides+ 2H2O2
lipase⎯ →⎯⎯ glycerol+ 3RCOOH
 Glycerol+ ATP
GK
Mg2+⎯ →⎯⎯ glycerol− 3phosphate + ADP
 Glycerol− 3− phosphate +O2
GPO⎯ →⎯⎯ dihydroxyacetone phosphate+H2O2
 
H2O2 + 4− a minophenazone + 4− cholorophenol
peroidase⎯ →⎯⎯⎯
4− (p− benzoquinone −monoimino)− phenazone + 2H2O+ Hcl
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Chylomincrons, VLDL (very low-density lipoprotein), and LDL (low-
density lipoprotein) are precipitated by adding phosphotungstic acid and 
magnesium ions to the sample. Centrifugation leaves only the HDL (high – 
density lipoproteins) in the supernatant; their cholesterol content is 
determined enzymatically. (Boehringer Mannheim GmbH Cat. 543004). 
In patients with high triglycerides values: the HDL cholesterol 
estimation was done after dilution of serum (1:1) with isotonic saline and the 
resultant cholesterol value of HDL-cholesterol was multiplied by 2. This was 
done to prevent the erroneous values of HDL-cholesterol due to impaired 
sedimentation of the precipitate in a serum with high triglycerides 
concentration. 
Clinical interpretation 
 Normal range – 35 to 55 mg % 
It is considered as a risk factor if HDL-cholesterol level was below 35 mg % 
4) LDL Cholesterol Estimation: 
LDL – cholesterol was calculated by using a standard WHO approved 
formula based on the total cholesterol, triglyceride and the HDL – 
cholesterol values. 
LDL cholesterol = Total cholesterol – (HDL + triglyceride/5) 
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Triglyceride/5 indicates the cholesterol in VLDL fraction and was 
used when the TG levels were below 400 mg/dI 
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5. STATISTICAL ANALYSIS 
The mean levels of various variables were correlated with basal 
reference for normal individuals. Relevant statistical methods like student ‘t’ 
test and whenever required Mann-Whitney test was used to see the 
significance of difference in mean values between groups and to know there 
correlation between inter and intra group variation. 
Ethical clearance was obtained from the ethical committee. 
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Table: 4  
Comparison of Lipid Profile among Smokers and Non Smokers 
Lipid Profile Non-Smokers (Mean ± Std) 
Smokers 
(Mean ± Std) P-Value 
TC 161.18±26.77 191.96±31.37 < 0.001 
TG 103.58±26.26 164.29±28.95 < 0.001 
HDL 49.58±8.57 44.72±9.96 = 0.002 
LDL 82.34±16.57 103.08±18.66 < 0.001 
VLDL 21.69±6.42 29.02±8.98 < 0.001 	  
Figure: 18  
Comparison of Lipid Profile among Smokers and Non Smokers 	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Table: 5 
Comparison of Lipid Profile depending on Intensity of Smoking 
Lipid Profile	   Smokers	  
Mild Moderate Severe 
TG 183.06±33.38 194.09±29.39 209±29.15 
TC 155.06±31.8 166±26.63 176.5±25.62 
HDL 48.03±8.65 45.06±10.26 42±9.67 
LDL 97.12±13.05 105.58±20.07 114±20.41 
VLDL 23.15±7.67 32.73±6.67 34±9.27 	  
Figure: 19 
Comparison of Lipid Profile depending on Intensity of Smoking 
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Table: 6 
Comparison of Lipid Profile among Non Smokers and Smokers 
(with respect to intensity of smoking) 
    Non-Smokers Mean±Std 
Smokers 
 Mean±Std p value 
TC 
Mild 161.18±26.77 183.06±67 < 0.05 
Moderate 161.18±26.77 194.09±29.39 < 0.001 
Severe 161.18±26.77 209±29.15 < 0.001 
TG 
Mild 103.58±26.26 155.06±68 < 0.001 
Moderate 103.58±26.26 166±26.63 < 0.001 
Severe 103.58±26.26 176.5±25.62 < 0.001 
HDL 
Mild 49.58±8.57 48.03±8.79 < 0.5 
Moderate 49.58±8.57 45.06±10.26 <0.07 
Severe 49.58±8.57 42±9.67 < 0.05 
LDL 
Mild 82.34±16.57 97.12±13.26 < 0.001 
Moderate 82.34±16.57 105.58±20.07 < 0.001 
Severe 82.34±16.57 114±20.41 < 0.001 
VLDL 
Mild 21.69±6.42 23.15±7.65 < 0.001 
Moderate 21.69±6.42 32.73±6.67 < 0.001 
Severe 21.69±6.42 34±9.27 < 0.001 	  
	  88	  
Figure: 20 
Comparison of Lipid Profile among Non Smokers and Smokers 
(With respect to intensity of smoking) 
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Table: 7 
Age Distribution of the Study Group 
 
 
 
(a) 
 
(b) 
Figure: 21.  
36%	  43%	  
21%	   Non-Smokers 21-­‐30	  31-­‐40	  41-­‐50	  
30%	  
49%	  
21%	  
Smokers 
21-­‐30	  31-­‐40	  41-­‐50	  
Age in Years No. of  Non-Smokers No. of Smokers 
21-30 36 30 
31-40 43 49 
41-50 21 21 
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Table: 8 
Comparison of Total Cholesterol among Smokers and Non-Smokers  
(Age wise) 
 Non-Smokers Smokers 
Age in Years No. of  Persons TC 
No. of  
Persons TC 
21-30 36 156.64±22.58 30 197.17±32.59 
31-40 43 163.84±29.21 49 191.45±29.72 
41-50 21 163.52±27.11 21 185.71±32.08 
 
Figure: 22 
Comparison of Total Cholesterol among Smokers and Non-Smokers  
(Age wise) 
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Table: 9 
Comparison of TG among Non-Smokers and Smokers  
(Age wise) 
 
 Non-Smokers Smokers 
Age in Years No. of  Persons TG 
No. of  
Persons TG 
21-30 36 101.75±21.51 30 171.33±29.16 
31-40 43 103.65±29.53 49 163.08±25.88 
41-50 21 106.57±26.3 21 157.05±32.97 
 
 
Figure: 23 
Comparison of TG among Non-Smokers and Smokers  
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Table: 10 
Comparison of HDL among Non-Smokers and Smokers  
(Age wise) 
 
 
 Non-Smokers Smokers 
Age in Years No. of  Persons HDL 
No. of 
 Persons HDL 
21-30 36 50.47±7.84 30 42.47±10.68 
31-40 43 48.88±9.34 49 44.98±8.96 
41-50 21 49.48±7.96 21 47.33±10.38 
 
Figure: 24 
Comparison of HDL among Non-Smokers and Smokers  
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Table: 11 
Comparison of LDL among Non-Smokers and Smokers  
(Age wise) 
 
 
 Non-Smokers Smokers 
Age in Years No. of  Persons LDL 
No. of  
Persons LDL 
21-30 36 80.44±16.55 30 107.23±19.95 
31-40 43 83.84±15.67 49 103.18±18.59 
41-50 21 82.52±17.99 21 96.9±14.88 
 
 
Figure: 25 
Comparison of LDL among Non-Smokers and Smokers  
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Table: 12 
Comparison of VLDL among Non-Smokers and Smokers  
(Age wise) 
 
 
 Non-Smokers Smokers 
Age in Years No. of  Persons VLDL 
No. of  
Persons VLDL 
21-30 36 20.44±6.2 30 30.7±10.12 
31-40 43 23.21±6.39 49 28.73±8.56 
41-50 21 20.71±6.21 21 27.29±7.73 
 
Figure: 26 
Comparison of VLDL among Non-Smokers and Smokers  
 
0.00 
5.00 
10.00 
15.00 
20.00 
25.00 
30.00 
35.00 
40.00 
45.00 
21-30 31-40 41-50 
V
L
D
L 
(m
g/
dl
) 
Age in years 
Non-Smokers 
Smokers 
	  95	  
 
Table: 13 
Comparison of HDL/TC among Non-Smokers and Smokers  
(Age wise) 
 Non-Smokers Smokers 
Age in years No. of  Persons HDL/TC 
No. of  
Persons HDL/TC 
21-30 36 0.33±0.1 30 0.23±0.09 
31-40 43 0.32±0.11 49 0.25±0.08 
41-50 21 0.32±0.08 21 0.27±0.1 
 
Figure: 27 
Comparison of HDL/TC among Non-Smokers and Smokers  
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6. DISCUSSION 
Cigarette smoking is found to occur mostly in later age group in 
Indian population when compared to western society. Third decade of life 
accounts for maximum number of smokers. In late adolescent periods and 
during college life they get captivated by the “ Kick of smoke”. Some start 
smoking to show off their macho image. Majority gets addicted to smoke but 
some people quit. Some go for other additive habits like cannabis. Smoking 
beedi is found mostly among the labor class in India. Smoking filtered tip 
cigarettes is found mostly among elite population. 
Several studies have been conducted both in India and abroad among 
the smokers and they analyzed their clinical, biochemical and pathological 
parameters. The present study was conducted with the aims of comparing 
the lipid profile among smokers and non-smokers and to study changes in 
lipid profile depending on the intensity of smoking. This study was done as a 
part of postgraduate training programme. 
Smokers are at a higher risk of CAD when compared to non-smokers. 
The various explanations given for this association includes alterations in 
blood coagulation, , reduced fibrinolysis, impaired arterial integrity and 
altered lipid profile and lipoprotein levels. The last explanation is examined 
in this study. Since in India smoking is less prevalent among females this 
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study was done only among male smokers. This discussion is planned to 
evaluate each variables separately. 
Comparison between smokers and non-smokers of different age groups: 
TOTAL CHOLESTEROL: 
In the age group of 21 to 30 (30 persons) the mean total cholesterol 
value was 197.17 in smokers, while in non-smokers it was 156.64 (36 
persons). In smokers of age group 31 to 40 (49 persons) the mean total 
cholesterol was 191.45 while in non-smokers it was 163.84(43 persons). The 
mean total cholesterol was 185.71 in smokers (21 persons) of age group 41 
to 50 years while it was 163.52 in non-smokers (21 persons). The 
association of an increased total cholesterol value with smoking was noticed 
when smokers were compared with non-smokers of the similar age group. 
The mean total cholesterol value was 191.96 in smokers (100 persons) and 
161.18 in non-smokers  (100 persons), P value <0.001. 
A study this kind comprising a very large number (that is more than 
50,000 participants) was done in 1988 by the American Health Foundation 
of USA. Cholesterol screening was made across the country. The data 
collected from 10 screening centers were combined. The mean cholesterol 
values and standard errors were calculated for each both sexes and for 
various age groups. The results of this study are given below: 
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1. For each sex the mean cholesterol values increased with age. 
2. For men, the mean cholesterol values increased gradually up to the 
age of 50 years, after which it appeared to be a plateau and then fell 
slightly. In both sexes mean cholesterol values decreased slightly after 
the age of 70 years, representing a possible survivorship effect. 
3. It was noted that with an increase in the severity of smoking there was 
a statistically significant increase in mean total cholesterol values. 
Among men in age group of 20-60, they found 0.34 mg/dl increase in 
total cholesterol for every cigarette smoked. In women strongest 
association was observed in age interval between 30 to 50 years, 
where serum cholesterol increased by 0.5 mg/dl for each cigarette 
smoked. 
These results indicated that heavy smokers of both sexes had 
considerably higher levels of plasma cholesterol than non-smokers, with the 
trend among women smokers aged 30-50 years greater than that for men and 
other women. For example, men under 50 years of age, who smoked 30 
cigarettes or more per day had a predicted level approximately 10mg/ dl 
higher than those who never smoked; and women in the 30-50 age group had 
15mg/dl values higher than non smokers. 
	  99	  
The AHF study had certain limitations. The cholesterol screening was 
designed to be rapid: statistical analysis depended on the accuracy of self-
reporting and the variables that might affect serum cholesterol levels were 
not collected. The explanation put forward by the AHF study were; 
1. Repressive effects on oestrogen levels resulting in higher 
cholesterol level. 
2. Differing pattern of inhalation in different age groups. 
3. Consuming low fiber containing cereals and foods and dietary 
increase of fat, coffee and alcohol. 
4. Sympathetic stimulation induced by nicotine leading to 
catecholamine release and further lipolysis. 
The present study is in accordance with the AHF study, as a linear 
relationship is seen in the data collected; the total cholesterol levels and the 
severity of smoking. Karvonen et al also has noted such a correlation 
between smoking and elevation of cholesterol. 
This study is also in accordance with study done by R.K. Tilwani, B. 
sapra, P.K.Sharma, R.K.Goyal in J.L.N.Medical college and A.G.Hospital, 
Ajmer, which showed increasing total cholesterol and severity of smoking. 
Similar results were noted by A.K.Sinha, G.C.Mishra, D.K.Paatel in their 
study on the same in V.S.S. Medical college, Orissa. Similar results were 
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observed in the study done by R.Rastogi and others in L.L.R.M. Medical 
College. 
HDL cholesterol: 
Of the smokers in 21-30 years of age group the mean value of HDL 
cholesterol stood 42.27mg/dl while the non-smokers showed a mean value 
of 50.47. Age related decrease was observed in the advancing age group 
probably due to increase in the duration of smoking. Smokers in the age 
group 31-40 years had mean HDL value of 44.98 mg/dl (49 persons), which 
is low compared to non-smokers of the same age group 48.88mg/dl (43 
persons). In the age group of 41-50 years the smokers had a mean HDL 
value of 47.33mg/dl (21 persons) while the non-smokers of the same age 
group had a mean HDL value of 49.48 (21 persons). The mean HDL in 
smokers was 44.72 mg/dl (100 persons) while the mean of non smokers was 
49.58 mg/dl  (100 persons). P value =0.002. 
Chemical pathology and medicine department of St. Marys hospital, 
London conducted a study and put forward an explanation to this effect. The 
action of endothelial lipoprotein lipase on triglyceride rich lipoprotein 
reduces the core volume of these particles and generates surface remnants 
containing unesterified cholesterol, phospolipid and apoprotein, which join 
the HDL3 pool. These surface remnants are thought to constitute the major 
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source of HDL precursors and lipoprotein lipase is thought to be a major 
determinant of plasma concentration of HDL. Esterification of the acquired 
free cholesterol in HDL3 particles by lecithin cholesterol acyltransferase 
results in the accumulation of cholesterol ester in the core of the particles 
and the production of larger, less dense HDL2 particles. 
A transfer protein mediates the exchange of cholesterol ester in HDL 
with triglyceride in lipoprotein of a lower density. The magnitude of 
postprandial lipaemia determines the extent of this exchange and resultant 
triglyceride content of HDL2 particles. Furthermore, the triglyceride content 
of HDL2 particles has been shown to determine, which of the phospholipase 
or triglyceride lipase activities of hepatic lipase act on them. Triglyceride 
rich HDL2 particles are converted to HDL3 particles by removal of the 
triglyceride from the core of the particles, whereas phospholipid is removed 
from the surface of triglyceride poor HDL2 particles without any change in 
size or density. 
Reduced intravascular lipolysis exists in smokers, hence it was 
suggested that a consequent increase in the postprandial lipaemia in smokers 
will result in a greater proportion being converted to HDL3 particles by 
hepatic lipase. This would explain the lowering of HDL2 and the increase in 
the concentration of HDL3 cholesterol found in smokers. 
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HDL2 concentration correlates negatively with the severity of 
angiographically defined atheroma. The change in HDL that is reported in 
young smokers and the increased exposure of vascular endothelium to the 
potentially atherogenic lipoproteins as a consequence of impaired clearance 
of triglyceride rich lipoproteins is the mechanism whereby smoking 
predisposes to coronary artery disease. 
The present study had not focused on HDL values following cessation 
of smoking. But data published by Moffatt R.J. et al and Quensel et al 
revealed normalization of HDL in smokers who gave up that habit. HDL 
values increased by 7mg/dl in 48days after stopping smoking and the effect 
disappeared in people who resumed the habit. 
The present results are in concordance with R.K. Tilwani et al study in 
J.L.N. Medical college and A.G. Hospital, Ajmer and also with study done 
by R.Rastogi and others in L.L.R.M. Medical college. A.K. Sinha and others 
reported similar results in their study conducted in V.S.S. Medical college, 
Orissa. 
LDL-cholesterol: 
Quantitative estimation of LDL in this study showed a mean value of 
107.23mg/dl in smokers of  21-30 years age group which comprised 30 
participants while the non smokers (36 persons) showed a value of 
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80.44mg/dl. The mean LDL values of smokers in the age group 31-40 (49 
persons) was 103.18mg/dl and that of non smokers of the same age group 
(43 persons) was 83.84mg/dl. The mean LDL values of smokers of the age 
group 41-50 was 96.9mg/dl and that of non smokers was 82.52mg/dl. The 
LDL values were high in the smokers compared with non-smokers of the 
same age group. The mean LDL value in smokers was 103.08mg/dl when 
compared with non smokers which was 82.34mg/dl. P-value (<0.001). 
To establish a causal relationship between exposure to cigarette 
smoke and changes in serum lipid and lipoprotein concentrations, dose-
response effects were calculated by an analysis of 54 published studies 
conducted by wendy Y.F. and his associates from the foundation of Blood 
research, scarbrough, USA. They found a higher mean concentration of 
cholesterol (3%), triglycerides (9.1%), VLDL (10.4%), LDL (1.7%). The 
dose response effect on VLDL and LDL among non smokers, mild, 
moderate and severe smokers were ( 0, 7.2 , 44.4, 39.0%) and (0 , -1.1, 1.4 , 
and 11.0%) respectively. 
This study results are comparable with LDL levels of R.Rastogi and 
other’s study on the same topic. R. Rastogi et al study showed higher levels 
of LDL in heavy smokers. Similar results were reported by A.K. Sinha and 
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associates in their study of effect of cigarette smoking on lipid profile in the 
young. 
TRIGLYCERIDES: 
In the age group of 21-30 years smokers (30 persons) showed a mean 
value of 171.33 mg/dl while the mean value of triglyceride in non-smokers 
was 101.75mg/dl in the same age group. In the 31-40 years age group mean 
value among smokers was 163.08mg/dl (49 persons): non-smokers showed 
103.65mg/dl (43 persons). The mean triglyceride value was 157.05mg/dl in 
smokers of age group 41-50 years (21 persons) and in non smokers it was 
106.57mg/dl (21 persons) . The mean value of TG in smokers was 
164.29mg/dl when compared to non-smokers, which was 103.58mg/dl. (p 
value <0.001). The triglycerides show a steady increase with increase in the 
severity of smoking. 
The Craig WY study on persons in 8-19 age groups had shown an 
increase of 11.8% in smokers for the triglyceride value while their analysis 
of the 54 published data showed an increase in triglyceride value of 9.1% in 
smokers compared to non-smokers. 
Sympatho adrenal system stimulation by nicotine leads to lipolysis 
and increased serum free fatty acid levels which lead to increased synthesis 
of VLDL from the liver and hence triglycerides. 
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These findings are also similar to those done by R.K. Tilwani (J.L.N. 
Medical college) and R. Rastogi L.L.R.M. Medical college. A.K. Sinha et al 
showed significant increase of LDL cholesterol in severe smokers. 
HDL to Total cholesterol: 
Several studies which have evaluated the risk factor for ischaemic 
heart disease has showed that reduced HDL–cholesterol to total cholesterol 
is a very important risk factor. The present study showed significant 
reduction in the HDL-C/TC ratio in smokers compared to non-smokers. The 
values in non smokers of age group 21-30, 31-40, 41-50 were 0.33±0.1, 
0.32±0.11, and 0.32±0.08, While in smokers of the same age group the 
values were 0.23±0.09, 0.25±0.08, 0.27±0.1 respectively which was 
significantly low. This is also in accordance with studies conducted abroad 
and in India. A Comparative study of HDL-c/TC ratio showed in 0.25 in 
smokers when compared to 0.32 in non-smokers.  
VLDL: 
The VLDL values of smokers of the age group 21-30, 31-40,41-50 
years were 30.7, 28.73, 27.29 mg/dl respectively. While the values in non-
smokers of the similar age group were 20.44, 23.21, 20.71mg/dl 
respectively.  The mean value in nonsmokers was 21.69 mg/dl while that of 
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smokers was 29.02 mg/dl . P value (<0.001). VLDL values show a steady 
increase with the severity of smoking. 
Comparision of values depending on the severity of smoking: 
The mean total cholesterol in mild smokers was 183.06±33.38 while 
that of moderate smokers was 194.09±29.39, and that of severe smokers was 
209±29.15. The cholesterol values were found to increase with increase in 
the severity of smoking. The mean triglyceride value of mild smokers was 
155.06±31.80, while that of moderate and severe smokers were 166±26.63 
and 176.5±25.62 respectively. With the increase in the severity of smoking 
there is increase in the triglyceride values. The mean HDL values of mild, 
moderate and severe smokers were 48.03±8.65, 45.06±10.26 and 42±9.67 
respectively. The HDL values show a steady decline with increase in the 
severity of smoking. The mean LDL values in mild, moderate and severe 
smokers were 97.12±13.05, 105.58±20.07, and 114±20.41 respectively. The 
values of LDL show a steady increase with increase in severity of smoking. 
The mean VLDL of mild, moderate and severe smokers were 23.15±7.67, 
32.73±6.67 and 34±9.27 respectively which show an increase in values with 
increased severity of smoking.  
The mean total cholesterol value of non-smokers was 161.18±26.77 
while that of smokers was 191.96±31.37. The mean triglyceride value of 
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non-smokers was 103.58±26.26 while in smokers it was 164.29±28.95. The 
mean HDL value of non-smokers was 49.58±8.57 while in smokers it was 
44.72±9.96. The mean LDL values of non-smokers was 82.34±16.57 while 
in smokers it was 103.08±18.66. The mean VLDL value of non-smokers 
was 21.69±6.42 while in smokers it was 29.02±8.98. The total cholesterol, 
triglyceride, LDL and VLDL values were significantly elevated in smokers 
when compared to the non-smokers. The HDL values were significantly 
lower in smokers when compared to the non-smokers. When HDL-C/TC 
ratio of smokers were 0.25 compared with that of non smokers which was 
0.32 , significantly lower levels were found in moderate and severe smokers.  
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7. CONCLUSION 
• Increase in total cholesterol, triglycerides, low-density lipoproteins 
and very low-density lipoproteins were found in smokers of all age 
group, whereas high-density lipoproteins showed an inverse 
relationship. 
• A direct relationship exists between the severity of smoking and 
increase in the total cholesterol, triglycerides, LDL and VLDL while 
an inverse relationship is found with HDL. 
• Asymptomatic smokers are at the risk of developing coronary artery 
disease due to the above changes in lipid profile. 
• The observed values were in concordance with the studies done in 
India and other countries. 
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8. LIMITATIONS OF THE STUDY 
 
Since the population selected for this study was small and the study is 
not a blinded study, an element of observer bias may have occurred. Large 
population studies should be conducted to confirm the results. 
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9. SUMMARY 
The present study was carried out among 200 patients who attended 
Madurai Rajaji Government Hospital. 100 smokers and 100 non-smokers 
were selected for this study. The study was conducted from July 2014 to 
September 2014.  
• All the patients studied were males. 
• The population was selected in the age group of 20 to 50 years. 
• Among non-smokers the mean value of total cholesterol was 
161.18±26.77, triglycerides was 103.58±26.26, HDL was 49.58±8.57, 
LDL was 82.34±16.57 and VLDL was 21.69±6.42. 
• Among mild smokers the mean value of total cholesterol was 
183.06±33.38, triglycerides was 155.06±31.80, HDL was 48.03±8.65, 
LDL was 97.12±13.05 and VLDL was 23.15±7.67.  
• Among moderate smokers the mean value of total cholesterol was 
194.09±29.39, triglyceride was166±26.63, HDL was 45.06±10.26, 
LDL was 105.58±20.07 and VLDL was 32.73±6.67. 
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• Among severe smokers the mean value of total cholesterol was 
209±29.15, triglycerides was 176.50±25.62, HDL was42±9.67, LDL 
was 114±20.41 and VLDL was 34±9.27. 
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PROFORMA 
A COMPARATIVE STUDY OF LIPID PROFILE AMONG SMOKERS 
AND NON-SMOKERS 
Case No : OP No : 
Name :  
Age / Sex : 
Occupation  : 
Religion  :  
Address  : 
Height  : 
Weight  : 
Date of Sampling : 
1. PRESENTING COMPLAINS: 
2. HISTORY OF PRESENTING ILLNESS: 
(Type, onset, duration, progression, present state of the 
complaints, associated features if any) 
3. PAST HISTORY: 
HT / DM / PTB / BA /I.H.D /Renal disease / Liver disease / 
Hyperlipidemia /Thyroid disorders /other 
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4. FAMILY HISTORY: 
- Hyperlipidemia 
- Death in the family due to diseases related to smoking  
- Death in the family due to ischemic heart disease           
5. DRUG HISTORY: 
If any specify, drug ______________ dose 
_______________ duration ______________ 
6. PERSONAL HISTORY 
Sleep : 
Appetite : 
Diet :  Vegetarian/Non-vegetarian 
Preference for fatty 
food in routine diet  :   Yes/No 
Bowel :           Bladder : 
History of smoking :    Yes/No 
Cigarettes/day : 
Beedies/day : 
Years of smoking     :     
(duration) 
History of alcohol in take  : Yes/No since 
History of betel nut chewing : Yes/No   since  
History of tobacco chewing : Yes/No since 
History of any other habits  : Yes/No since 
(If Yes Specify) 
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7. GENERAL EXAMINATION:  
a) Built : Well/moderately/poorly 
b) Nourishment   : Under nourished/Normal/obese 
c) Anemic[pallor]  : Yes/No 
d) Jaundice[icterus]  : Yes/No  
e) Clubbing  : Yes/No 
f) Oedema  : Yes/No 
g) Lymphadenopathy  : Yes/No 
h) Eyes: Arcus Senilis  : Yes/No 
i) Thyroid  : Normal/Enlarged 
j) Opticfundus  : Normal / 
    Hypertensive  /Diabetic 
k) BP  : 
l) Pulse  : Rate            :  
    Rhythm  : 
    Character  :  
    Volume        : 
    Condition of the vessel wall :  
m) J.V.P : 
n) Respiratory rate : 
o) Temperature : 
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p) Body mass index : 
8. SYSTEMIC EXAMINATIONS: 
a)   Cardiovascular examination: 
Inspection: 
- Shape of the chest /Any deformity 
- Precordium 
- Apical impulse 
- Visible pulsation 
Palpation: 
- Apex beat  : Size 
Character 
Thrill 
Palpable sounds 
- Left parasternal heave : Present/absent 
- 2ndleft intercostal space 
Palpable s2 :  Thrill : 
- Other areas : 
Auscultation 
 
S1,S2 :  Normal/Abnormal/ Specify 
 
S3 : Yes/No 
 
S4 : Yes/No 
 
Murmurs : Absent/Present 
    
    Specify 
 
 
b)  Respiratory system  : Normal/Abnormal 
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  If abnormal specify 
 
c)  Gastro-intestinal system  : Normal/Abnormal  
If abnormal specify 
 
 
         d) Nervous system   : Normal/Abnormal 
 
    If abnormal specify  
         e) Genitourinary system : Normal/Abnormal 
    If abnormal specify 
9.INVESTIGATIONS: 
a) Fasting Blood Sugar : 
b) Post Prandial Blood : 
Sugar 
 
c) Blood urea   :   
d) Serum creatinine   : 
e) Lipid profile 
- Total Cholesterol : 
- LDL : 
- HDL : 
- Serum Triglycerides : 
- VLDL  : 
f) Thyroid P r o f i l e   :  
g) Electrocardiogram : 
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MASTER CHART 
NON-SMOKERS 
S.NO Name AGE (yrs) TC TG HDL LDL VLDL 
1 Akbar 25 161 111 57 80 24 
2 Aandy 40 137 101 55 79 30 
3 suresh 30 123 92 51 78 19 
4 Mohamed Ali 37 180 159 38 108 28 
5 Ajith 29 102 81 56 63 12 
6 Arumugam 32 145 100 58 85 25 
7 Chinna Mayan 26 143 118 46 90 23 
8 Eswaran 36 167 122 42 99 31 
9 Ganesh 45 187 163 36 126 28 
10 Hariharan 23 201 170 40 151 40 
11 Ram Chandar 34 128 72 56 70 22 
12 Jeya Singh 38 163 130 49 85 27 
13 Nagaraj 49 150 102 47 90 16 
14 Irulandi 23 125 75 49 90 22 
15 Dharmaraj 39 175 87 53 112 28 
16 Kesavan 30 144 130 46 88 20 
17 Chandra Mouli 32 192 166 40 109 31 
18 Bhagiyaraj 34 121 69 53 75 14 
19 Alagar Samy 23 166 120 48 99 28 
20 Alaudeen 31 161 90 49 85 20 
21 Karuppa Samy 24 176 85 43 92 28 
22 Kulanthai Velu 40 155 78 50 67 19 
23 Maharajan 43 133 66 54 54 14 
24 Mohan Kumar 32 188 123 36 85 25 
25 Rajkumar 23 166 103 49 76 18 
26 Sivakumar 32 197 106 38 99 29 
27 Ramar 45 154 87 43 61 17 
28 Ravi 37 258 169 30 115 40 
29 Aswin 25 177 98 47 78 29 
30 Singamuthu 39 182 101 34 94 24 
31 Essakki 26 153 84 54 89 18 
32 Veera Kumar 36 199 109 33 103 28 
33 Savior 44 142 79 49 71 16 
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S.NO Name AGE (yrs) TC TG HDL LDL VLDL 
34 Chandhana Mariappan 21 172 98 45 86 22 
35 Santhanam 40 165 95 50 83 21 
36 Alagu 36 137 60 61 54 16 
37 Ponnu samy 26 149 76 56 60 19 
38 Prabhakar 48 151 89 50 74 20 
39 Rathinam 32 189 109 42 94 23 
40 Mayandi 42 162 101 48 88 21 
41 Ruthreshwar 27 169 94 53 81 17 
42 Manikkam 25 141 85 51 80 12 
43 Priyadharsan 23 170 116 32 92 19 
44 Maniratham 46 240 172 30 112 30 
45 Panneer Selvam 39 162 89 47 91 27 
46 Rahuman 25 148 82 58 63 12 
47 Rajesh 40 139 76 59 59 15 
48 Surya 21 160 99 39 75 19 
49 Senthil Ganesh 32 157 90 42 62 20 
50 Manikandan 28 170 117 45 69 13 
51 Subramani 33 129 70 61 67 19 
52 Arunachalam 49 183 127 51 83 25 
53 Daniel Rajan 22 165 97 42 79 17 
54 Selvam 29 180 128 44 93 26 
55 Kannan 50 172 98 53 90 28 
56 Prasanna 35 156 99 48 76 16 
57 Marimuthu 33 149 96 52 79 19 
58 Kumar 30 170 111 58 87 24 
59 Veerachamy 50 203 138 36 107 37 
60 Muthu Veeran 33 168 95 49 75 26 
61 Irrulandi 47 130 81 53 58 15 
62 Maha Kumar 25 183 118 30 92 29 
63 Janardhanan 23 120 71 60 55 14 
64 Alphonse 39 194 142 33 96 31 
65 Antony Raj 41 177 103 52 85 20 
66 Ahamed Mohideen 32 160 100 50 89 18 
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S.NO Name AGE (yrs) TC TG HDL LDL VLDL 
67 Moorthi 30 186 131 48 91 31 
68 Sivanantha prabhu 27 155 93 59 88 20 
69 Manivannan 37 183 129 40 92 28 
70 Sathyamoorthi 27 136 87 58 70 14 
71 Sankaranarayana 31 190 144 46 96 29 
72 Raja 28 158 96 52 71 16 
73 Rakesh 43 168 90 44 81 21 
74 Murugan 33 122 58 63 60 17 
75 Dharmaprabhu 39 197 135 42 93 27 
76 Indrian 28 169 89 52 62 26 
77 Veeriyan 38 144 92 49 82 18 
78 Gnaprakash 46 195 128 49 99 23 
79 Mookandi 33 120 90 64 66 13 
80 Janakarajan 25 141 110 62 71 15 
81 Biju 44 173 104 54 97 26 
82 Boominathan 32 130 98 59 68 14 
83 Gowthan 37 185 106 53 80 23 
84 Samy 49 151 101 58 74 18 
85 Samuthirakani 29 176 120 59 88 22 
86 Anbarasu 38 140 81 60 65 24 
87 Deva 32 153 89 60 70 20 
88 Thiagarajan 24 178 84 52 63 16 
89 Soundara Pandi 50 145 76 61 75 18 
90 Selvakumar 32 122 56 62 68 15 
91 Bhootham 27 165 114 56 69 18 
92 Velu 39 171 144 52 80 20 
93 Alagu Raja 43 132 111 51 64 11 
94 Ragupathi 22 140 124 56 77 21 
95 Michel 45 128 110 59 68 16 
96 Rajendran 40 170 90 52 95 20 
97 Joesph 39 140 74 58 81 18 
98 Narasiman 21 101 56 64 60 13 
99 Vijay 43 158 112 61 76 15 
100 Akilesh 31 225 168 34 114 40 
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SMOKERS 
MILD SMOKERS 
S.NO Name AGE (yrs) TC TG HDL LDL VLDL 
1 Rajkumar 34 170 151 50 92 20 
2 Maha Krishna 41 254 221 31 119 31 
3 Mahesh 50 150 130 53 88 15 
4 Veerachamy 33 138 115 55 89 21 
5 Usman 39 220 197 32 120 32 
6 Pitcahai 44 188 158 54 100 20 
7 Rangan 22 127 103 59 76 19 
8 Selva Alagar 40 175 138 57 94 21 
9 Singaraj 45 199 172 46 97 38 
10 Palanivel 36 220 196 32 103 32 
11 Muthalagan 30 171 139 49 100 16 
12 Karthikeyan 33 182 149 55 99 21 
13 Krishnanmoorthy 23 196 164 48 99 20 
14 Rajasekar 37 176 145 54 89 19 
15 Athidya 34 184 156 42 90 21 
16 Vikraman 47 195 160 46 93 18 
17 Udayakumar 22 168 149 57 96 23 
18 Prabhu 31 292 251 31 144 45 
19 Devaraj 36 162 143 49 92 16 
20 Srinivasan 29 183 147 42 94 21 
21 Ravikumar 33 143 146 56 98 18 
22 Sekar 49 190 164 52 97 21 
23 Abubacker 25 149 143 60 85 21 
24 Balaji 36 186 151 47 94 17 
25 Justin 29 208 190 34 108 32 
26 Thangapandi 39 192 158 51 103 19 
27 Sridhar 46 116 65 61 75 14 
28 Manimaran 35 180 153 49 98 22 
29 Ramu 30 167 142 50 96 18 
30 Babu Ganesh 40 179 146 49 87 32 
31 Vivekanandan 34 212 167 34 116 42 
32 Asan Mohideen 21 189 151 52 94 19 
33 Sudhakar 32 180 157 48 80 20 
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MODERATE SMOKERS 
S.NO Name AGE (yrs) TC TG HDL LDL VLDL 
34 Solomon 29 192 148 51 120 29 
35 Mohamed Faizal 35 198 162 45 132 26 
36 Muthu Vel 27 182 165 44 101 23 
37 Ravi Varman 21 201 159 38 122 40 
38 Mohan Prasanth 34 156 132 52 78 26 
39 Nagarajan 44 188 145 54 92 32 
40 PetchiMuthu 40 234 192 31 129 31 
41 Vinodan 23 140 132 59 85 27 
42 Mari Selvan 31 170 149 52 78 31 
43 Siva Raman 26 233 198 34 131 45 
44 Anoop Chandran 32 182 152 49 111 37 
45 Prakash 30 205 188 33 107 38 
46 Senthoor Pandi 34 222 194 31 134 46 
47 Alagesan 29 193 171 54 120 37 
48 Tamil Kumaran 45 178 146 49 97 26 
49 Rajarathan 35 228 182 36 127 43 
50 Sankaralingan 49 187 151 58 97 33 
51 Rajasingh 39 179 149 55 88 26 
52 Praveen 24 242 196 28 122 32 
53 Sambantham 39 190 161 46 102 26 
54 Alhaj 33 189 167 52 92 32 
55 Velraj 29 243 204 29 125 39 
56 Udayam 34 270 248 28 146 48 
57 Kalimuthu 40 167 146 41 89 29 
58 Amudan 47 209 199 35 100 36 
59 Oliyarasu 41 159 146 53 95 25 
60 Arjun 31 189 158 55 115 32 
61 Pankaj Kumar 27 192 170 39 98 38 
62 Manoj 37 134 112 60 68 23 
63 Devadoss 22 181 160 57 62 27 
64 Mannan 32 170 150 51 96 28 
65 Ramasamy 27 213 198 32 124 34 
66 Mathivaanan 37 189 148 56 101 35 
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SEVERE SMOKERS 
S.NO Name AGE (yrs) TC TG HDL LDL VLDL 
67 Manivanna Bhoopathi 38 230 196 30 130 36 
68 Raja Sekaran 28 178 150 55 82 22 
69 Jeya Chandram 40 200 176 35 112 30 
70 Arumuga Nainar 29 180 179 39 92 23 
71 Vishnu Chandar 31 198 165 34 99 28 
72 Nagendran 45 256 217 26 143 43 
73 David 27 172 148 43 94 19 
74 Paraman 33 145 143 52 80 14 
75 Bakthavatsalam 29 256 221 28 141 41 
76 Anbumani 34 181 160 50 93 17 
77 Thilagaraj 50 169 151 56 88 20 
78 Vasudevan 28 213 190 34 118 31 
79 Mokkasamy 39 197 159 39 98 27 
80 Gopinath 30 244 219 30 132 49 
81 Sellakannu 45 169 149 57 91 24 
82 Thirumalai 40 196 162 45 87 33 
83 Vinayakam 30 243 199 33 139 50 
84 Ravi 35 199 179 45 129 41 
85 Kirubakaran 44 190 160 35 86 35 
86 Lakhmi Narayanan 50 225 199 32 123 31 
87 Mathusudhanan 38 185 160 48 92 19 
88 Vikaram kumar 29 203 189 34 112 46 
89 Kathiravan 35 177 159 49 89 29 
90 Chinnadurai 50 150 145 59 78 23 
91 Siddarth 40 193 156 44 95 36 
92 Sundar 30 251 228 29 142 42 
93 Thiruvengadam 32 202 181 32 125 29 
94 Manokaran 42 174 145 51 89 25 
95 Linkeshwaran 36 187 150 47 101 22 
96 Peter 47 160 121 52 88 27 
97 Sathesh 37 239 196 31 140 40 
98 Arokiaraj 50 194 154 34 99 36 
99 Ramesh 33 206 171 38 114 38 
100 Mahadevan 37 188 157 54 98 32 
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